

STN SEARCH TRANSCRIPT

10/171,725

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 8 JAN 30 Saved answer limit increased
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 11 FEB 22 Updates in EPPFULL; IPC 8 enhancements added
NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 13 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
property data
NEWS 16 MAR 01 INSPEC reloaded and enhanced
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006
NEWS 19 MAR 22 EMBASE is now updated on a daily basis
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 23 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24 APR 12 Improved structure highlighting in FOHIT and QHIT display
in MARPAT
NEWS 25 APR 12 Derwent World Patents Index to be reloaded and enhanced during
second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementationof commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:27:26 ON 25 APR 2006

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

1.89

1.89

FILE 'REGISTRY' ENTERED AT 13:32:58 ON 25 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0

DICTIONARY FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *


Structure search iteration limits have been increased. See HELP SLIMITS
for details.REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\HONG'S IMIDAZOLES DIV.str



chain nodes :
6 9 10 11 12 13 23 27 28
ring nodes :
1 2 3 4 5 14 15 16 17 18 19 20 21 22
ring/chain nodes :
7
chain bonds :
2-6 6-7 6-27 9-10 10-11 11-12 12-13 20-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-15 14-19 15-16 16-17 17-18 18-19 18-20 19-22
20-21 21-22
exact/norm bonds :
1-2 1-5 2-3 3-4 6-7 6-27 12-13 19-22 21-22
exact bonds :
2-6 4-5 9-10 10-11 11-12 18-20 20-21 20-23
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 1 : 14 :

G1: [*1], [*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> D L1

L1 HAS NO ANSWERS

L1 STR



G1 [*1], [*2]

Structure attributes must be viewed using STN Express query preparation.

=> S L1 SSS FULL

FULL SEARCH INITIATED 13:33:19 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2372 TO ITERATE

100.0% PROCESSED 2372 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.02

L3

0 SEA SSS FUL L1

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 8 JAN 30 Saved answer limit increased
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 11 FEB 22 Updates in EPPFULL; IPC 8 enhancements added

NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 13 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16 MAR 01 INSPEC reloaded and enhanced
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006
NEWS 19 MAR 22 EMBASE is now updated on a daily basis
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 23 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 08:31:13 ON 26 APR 2006

	SINCE FILE ENTRY	TOTAL SESSION
=> file reg		
COST IN U.S. DOLLARS	0.21	0.21
FULL ESTIMATED COST		

FILE 'REGISTRY' ENTERED AT 08:31:17 ON 26 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6
DICTIONARY FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

.....
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
.....

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UQ/regprope.html>

=> PREVIOUS STRUCTURE SEARCH ***** WAS INCORRECT - SUPPOSED TO BE INDOLYL-3-YL-CH2- AND BUTYLAMINO, NOT PENTYLAMINO
PREVIOUS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=).
=>

.....Testing the current file..... screen

ENTER SCREEN EXPRESSION OR (END):end

=> Uploading C:\Program Files\Stnexp\Queries\HONG'S IMIDAZOLES DIV.str



chain nodes :
6 9 10 11 12 13 23 27 28
ring nodes :
1 2 3 4 5 14 15 16 17 18 19 20 21 22
ring/chain nodes :
7
chain bonds :
2-6 6-7 6-27 9-10 10-11 11-12 12-13 20-23

ring bonds :
1-2 1-5 2-3 3-4 4-5 14-15 14-19 15-16 16-17 17-18 18-19 18-20 19-22
20-21 21-22
exact/norm bonds :
1-2 1-5 2-3 3-4 6-7 6-27 12-13 19-22 21-22
exact bonds :
2-6 4-5 9-10 10-11 11-12 18-20 20-21 20-23
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 1 : 14 :

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 27:CLASS 28:CLASS 29:CLASS



L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> D L1

L1 HAS NO ANSWERS
L1 STR



G1
G2 [*1],[*2]

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 08:32:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 200 TO ITERATE

100.0% PROCESSED 200 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3152 TO 4848
PROJECTED ANSWERS: 1418 TO 2622

L3 50 SEA SSS SAM L1

=>Testing the current file..... screen

ENTER SCREEN EXPRESSION OR (END):end

=> Uploading C:\Program Files\Stnexp\Queries\HONG'S IMIDAZOLES DIV.str



chain nodes :
6 9 10 11 12 13 23 27 28
ring nodes :
1 2 3 4 5 14 15 16 17 18 19 20 21 22
ring/chain nodes :
7
chain bonds :
2-6 6-7 6-27 9-10 10-11 11-12 12-13 20-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-15 14-19 15-16 16-17 17-18 18-19 18-20 19-22
20-21 21-22
exact/norm bonds :
1-2 1-5 2-3 3-4 6-7 6-27 12-13 19-22 21-22
exact bonds :
2-6 4-5 9-10 10-11 11-12 18-20 20-21 20-23
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :

containing 1 : 14 :

G1: [*1], [*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 27:CLASS 28:CLASS 29:CLASS

L4 STRUCTURE UPLOADED




=> que L4

L5 QUE L4

=> D L4

L4 HAS NO ANSWERS

L4 STR



G1

G2 [G1], [G2]

Structure attributes must be viewed using STN Express query preparation.

=> S L4

SAMPLE SEARCH INITIATED 08:34:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 200 TO ITERATE

100.0% PROCESSED 200 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3152 TO 4848
PROJECTED ANSWERS: 1418 TO 2622






L6 50 SEA SSS SAM L4

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\HONG'S IMIDAZOLES DIV.etr



chain nodes :

6 9 10 11 12 13 23 27 28

ring nodes :

1 2 3 4 5 14 15 16 17 18 19 20 21 22

ring/chain nodes :

7

chain bonds :

2-6 6-7 6-27 9-10 10-11 11-12 12-13 20-23

ring bonds :

1-2 1-5 2-3 3-4 4-5 14-15 14-19 15-16 16-17 17-18 18-19 18-20 19-22

20-21 21-22

exact/norm bonds :

1-2 1-5 2-3 3-4 6-7 6-27 12-13 19-22 21-22

exact bonds :

2-6 4-5 9-10 10-11 11-12 18-20 20-21 20-23

normalized bonds :

14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 14 :

G1: [*1], [*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 27:CLASS 28:CLASS 29:CLASS

L7 STRUCTURE UPLOADED




=> que L7

L8 QUE L7

=> D L7

L7 HAS NO ANSWERS

L7 STR



G1 [G1], [G2]

Structure attributes must be viewed using STN Express query preparation.

=> S L7

SAMPLE SEARCH INITIATED 08:38:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 200 TO ITERATE

100.0% PROCESSED 200 ITERATIONS
SEARCH TIME: 00.00.01

36 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3152 TO 4848
PROJECTED ANSWERS: 360 TO 1080

L9 36 SEA SSS SAM L7

=> S L7 SSS FULL

FULL SEARCH INITIATED 08:38:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3915 TO ITERATE

100.0% PROCESSED 3915 ITERATIONS
SEARCH TIME: 00.00.02

655 ANSWERS

L10 655 SEA SSS FUL L7

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.22

172.43

FILE 'CAPLUS' ENTERED AT 08:39:01 ON 26 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 25 Apr 2006 (20060425/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L10

L11 32 L10

=> D 1-32 IBIB ABS HITSTR

L11 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:140811 CAPLUS

DOCUMENT NUMBER: 142:240429

TITLE:

Five-membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments Chabrier De Lasseuniere, Pierre-etienne; Harnett, Jeremiah; Bigg, Dennis; Liberatore, Ann-Marie; Pommier, Jacques; Lannoy, Jacques; Thuriel, Christophe; Dong, Zheng Xin

PATENT ASSIGNER(S):

Fr.

SOURCE:

U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. 681,002.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005038087	A1	20050217	US 2004-915001	20040810
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801

WO 2001026656 A2 20010419 WO 2000-FR2805 20001010
 WO 2001026656 A3 20020418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OL, OM, OS, PA, PE, PG, PH, PL, PT, PU, PY, RE, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TO

EP 1228760 A2 20020807 EP 2002-76763 20001010
 EP 1228760 A3 20040128

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

EP 1589007 A2 20051026 EP 2005-76749 20001010
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY

FR 2823208 A1 20021011 FR 2001-4943 20010410
 FR 2823208 B1 20040319

WO 2002083656 A2 20021024 WO 2002-FR1218 20020409
 WO 2002083656 A3 20030103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TO

ZA 2003007750 A 20040726 ZA 2003-7750 20031003
 US 2004132788 A1 20040708 US 2003-681002 20031008
 WO 2005035510 A1 20050421 WO 2004-FR2537 20041008

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, ZM


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO

PRIORITY APPLN. INFO.:

FR 1999-12643 A 19991011
 FR 2000-10151 A 20000801
 FR 2000-11169 A 20000901
 WO 2000-FR2805 W 20001010
 FR 2001-4943 A 20010410
 FR 2002-1811 A 20020214
 US 2002-89993 A2 20020404
 WO 2002-FR1218 A1 20020409
 US 2003-681002 A2 20031008
 EP 2000-967988 A3 20001010
 US 2004-915001 A 20040810

OTHER SOURCE(S):
 GI

MARPAT 142:240429



AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-Q [I; wherein the substituted heterocyclic ring Het(A)(B) = Q¹-Q⁴; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S;

n = 0-6; R₁, R₂ = especially H, alkyl, or cycloalkyl; Q = NR₃R₄ or OR₅; R₃ and R₄ = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl or (cycloalkyloxy)alkyl; R₅ = H, alkyl, alkynyl, or cyanoalkyl. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, or pain. Approx. 500 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P2S5)₂ in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and salification (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex preps., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.


IT 335242-96-1P, (1R)-N-Benzyl-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine 335243-06-6P, (1R)-tert-Butyl [1-(4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl]carbamate 335243-44-2P, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-49-7P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine 335243-63-5P, (1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethylaminehydrochlorid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)


RN 335242-96-1 CAPLUS
 CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-06-6 CAPLUS
 CN Carbamic acid, [(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-44-2 CAPLUS
 CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-49-7 CAPLUS
 CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-63-5 CAPLUS
 CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl


IT 252279-11-1, (1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethylamine 335246-48-5, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USSS (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 252279-11-1 CAPLUS
 CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-48-5 CAPLUS
 CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, (9CI) (CA INDEX NAME)



IT 335247-36-4, (1R)-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (precursor; preparation of five-membered heterocycle deriva. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 335247-36-4 CAPLUS
 CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:550745 CAPLUS
 DOCUMENT NUMBER: 141:106475
 TITLE: Preparation of 5-membered heterocycle derivatives for treating neurodegenerative disorders or pain
 INVENTOR(S): Chabrier De Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Bigg, Dennis; Liberatore, Anne-Marie; Pommier, Jacques; Lannoy, Jacques; Thuriereau, Christophe
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S. Ser. No. 89,993.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW


or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus, 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]amino]ethanethioamide (4.3 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atmosphere and stirred at ambient temperature for 12 h to give, after

workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-2-thiazolemethanamine which was treated with CF₃CO₂H and triethylsilane in 50 mL CH₂Cl₂ to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC₅₀ of lower than 10 μ M for inhibiting lipid peroxidn. of the cerebral cortex of rats.

IT 335247-36-4P, (1R)-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of 5-membered heterocycle deriva. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 335247-36-4 CAPLUS
 CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252279-11-1P, [(1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl]amine 335242-96-1P 335243-06-6P
 335243-49-7P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine 335243-63-5P, [(1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl]amine hydrochloride 335246-48-5P 717914-21-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses)

(preparation of 5-membered heterocycle deriva. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 252279-11-1 CAPLUS
 CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1228760 A2 20020807 EP 2002-76763 20001010
 EP 1228760 A3 20040128
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
 EP 1589007 A2 20051026 EP 2005-76749 20001010
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY
 FR 2823208 A1 20021011 FR 2001-4943 20010410
 FR 2823208 B1 20040319
 ZA 2003007750 A 20040726 ZA 2003-7750 20031003
 US 2005038067 A1 20050217 US 2004-915001 20040810
 WO 2005035510 A1 20050421 WO 2004-FR2537 20041008

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

FR 1999-12643 A 19991011
 FR 2000-10151 A 20000801
 FR 2000-11169 A 20000901
 WO 2000-FR2805 W 20001010
 FR 2001-4943 A 20010410
 FR 2002-1811 A 20020214
 US 2002-89993 A2 20020404
 EP 2000-967988 A3 20001010
 WO 2002-FR1218 A1 20020409
 US 2003-681002 A2 20031008
 US 2004-915001 A 20040810


OTHER SOURCE(S): MARPAT 141:106475
 GI



AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) [wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph; R1, R2 = H, alkyl, cycloalkyl; Q = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl]. These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipidic peroxidn. and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis


RN 335242-96-1 CAPLUS
 CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-06-6 CAPLUS
 CN Carbamic acid, [(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-49-7 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-63-5 CAPLUS
 CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• x HCl

RN 335246-48-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)



RN 717914-21-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-,
monohydrochloride (9CI) (CA INDEX NAME)




• HCl

L11 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:642410 CAPLUS
DOCUMENT NUMBER: 139:335874
TITLE: Increased skin collagen extractability and proportions of collagen type III are not normalized after 6 months healing of human excisional wounds
AUTHOR(S): Robins, Simon P.; Milne, George; Duncan, Alexander; Davies, Claire; Butt, Richard; Greiling, Doris; James, Ian T.
CORPORATE SOURCE: Matrix Biochemistry, Rowett Research Institute, Aberdeen, UK
SOURCE: Journal of Investigative Dermatology (2003), 121(2), 267-272
CODEN: JIDEAR; ISSN: 0022-202X
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In an attempt to identify potential staging markers of effective healing, changes in connective tissue properties were measured in a human skin excisional wound healing model in which tissue was re-excised at intervals up to 6 mo after injury. The proportion of collagen III relative to collagen I increased significantly ($p < 0.001$) up to 6 wk after initial injury and remained elevated up to 6 mo, at which time the proportion of collagen III was 70% above baseline values. Extractability of biopsy tissue collagen by pepsin increased significantly throughout the study (baseline, 32.8 \pm 6.8%; 6 mo, 89.1 \pm 8.9%), with inverse changes in the mature skin cross-link, histidinohydroxylysineonorleucine (baseline, 1.18 \pm 0.11 mol/mol collagen; 6 mo, 0.27 \pm 0.09 mol/mol collagen). Pyridinoline content increased over the period of the study, although remaining at relatively low concns. (baseline, 0.037 \pm 0.011; 6 mo, 0.063 \pm 0.014 mol/mol collagen), and the pyridinoline/deoxypyridinoline ratio was significantly higher (baseline, 3.5 \pm 0.6; 6 mo, 10.3 \pm 2.2). Elastin content, measured as desmosine cross-links, decreased significantly in the first 3 wk and continued to decline over the period of study. Overall, the data suggest that remodeling of the wound tissue continues at least up to 6 mo after injury. The close inverse correlation between histidinohydroxylysineonorleucine concns. and extractability by pepsin ($r^2 = 0.89$, $p < 0.0001$) suggests a causal relationship, consistent with the likely effects of a substantial network of mature, inter-helical bonds in collagen.

IT 108212-74-4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increased skin collagen extractability and proportions of collagen type III are not normalized after 6 mo healing of human excisional wounds in relation to)
RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, α -amino-4-(2-amino-2-carboxyethyl)-
c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:107321 CAPLUS
DOCUMENT NUMBER: 136:167373
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors
INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moine, Christophe Philippe; Bigg, Dennis
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 369 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2002010140 A2 20020207 WO 2001-US23959 20010731
WO 2002010140 A3 20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2417204 AA 20020207 CA 2001-2417204 20010731
EP 1305294 A2 20030502 EP 2001-957342 20010731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004518613 T2 20040624 JP 2002-516272 20010731
NZ 523774 A 20040924 NZ 2001-523774 20010731
NO 2003000473 A 20030130 NO 2003-473 20030130
PRIORITY APPLN. INFO.: US 2000-222584P P 20000801
WO 2001-US23959 W 20010731
OTHER SOURCE(S): MARPAT 136:167373
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Imidazole derivs. I [R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo(b)thiophene, Ph, naphthyl, etc.; m = 0-6; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mA1; A1 = C(Y)NX1X2; C(Y)X2; C(NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.], which are useful as agonists or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furanocarboxylic acid with carbonyldiimidazole followed by addition of 2-[(1S)-1-amino-2-(indol-3-yl)ethyl]-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.
IT 252315-86-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252315-86-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252279-11-1P 252292-81-2P 252292-82-3P
252292-83-4P 252292-84-5P 252292-85-6P
252292-86-7P 252292-87-8P 252292-88-9P
252292-89-0P 252292-90-1P 252292-91-2P
252292-92-3P 252292-93-4P 252292-94-5P
252292-95-6P 252292-96-7P 252292-97-8P
252292-98-9P 252292-99-0P 252293-00-1P
252293-01-2P 252293-02-3P 252293-03-4P
252293-04-5P 252293-05-6P 252293-06-7P
252293-07-8P 252293-08-9P 252293-09-0P
252293-10-1P 252293-11-2P 252293-12-3P
252293-13-4P 252293-14-5P 252293-15-6P
252293-16-7P 252293-17-8P 252293-18-9P
252293-19-0P 252293-20-1P 252293-21-2P
252293-22-3P 252293-23-4P 252293-24-5P
252293-25-6P 252293-26-7P 252293-27-8P
252293-28-9P 252293-29-0P 252293-30-1P
252293-31-2P 252293-32-3P 252293-33-4P
252293-34-5P 252293-35-6P 252293-36-7P
252293-37-8P 252293-38-9P 252293-39-0P
252293-40-1P 252293-41-2P 252293-42-3P
252293-43-4P 252293-44-5P 252293-45-6P
252293-46-7P 252293-47-8P 252293-48-9P
252293-49-0P 252293-50-1P 252293-51-2P
252293-52-3P 252293-53-4P 252293-54-5P
252293-55-6P 252293-56-7P 252293-57-8P
252293-58-9P 252293-59-0P 252293-60-1P
252293-61-2P 252293-62-3P 252293-63-4P
252293-64-5P 252293-65-6P 252293-66-7P
252293-67-8P 252293-68-9P 252293-69-0P
252293-70-1P 252293-71-2P 252293-72-3P
252293-73-4P 252293-74-5P 252293-75-6P
252293-76-7P 252293-77-8P 252293-78-9P
252293-79-0P 252293-80-1P 252293-81-2P
252293-82-3P 252293-83-4P 252293-84-5P
252293-85-6P 252293-86-7P 252293-87-8P
252293-88-9P 252293-89-0P 252293-90-1P
252293-91-2P 252293-92-3P 252293-93-4P
252293-94-5P 252293-95-6P 252293-96-7P
252293-97-8P 252293-98-9P 252293-99-0P
252294-00-1P 252294-01-2P 252294-02-3P
252294-03-4P 252294-04-5P 252294-05-6P
252294-06-7P 252294-07-8P 252294-08-9P
252294-09-0P 252294-10-1P 252294-11-2P
252294-12-3P 252294-13-4P 252294-14-5P
252294-15-6P 252294-16-7P 252294-17-8P
252294-18-9P 252294-19-0P 252294-20-1P
252294-21-2P 252294-22-3P 252294-23-4P
252294-24-5P 252294-25-6P 252294-26-7P
252294-27-8P 252294-28-9P 252294-29-0P
252294-30-1P 252294-31-2P 252294-32-3P
252294-33-4P 252294-34-5P 252294-35-6P
252294-36-7P 252294-37-8P 252294-38-9P
252294-39-0P 252294-40-1P 252294-41-2P
252294-42-3P 252294-43-4P 252294-44-5P
252294-45-6P 252294-46-7P

252294-47-6P 252294-48-7P 252294-49-8P
 252294-50-1P 252294-51-2P 252294-52-3P
 252294-53-4P 252294-54-5P 252294-55-6P
 252294-56-7P 252294-57-8P 252294-59-0P
 252294-60-3P 252294-61-4P 252294-62-5P
 252294-63-6P 252294-64-7P 252294-65-8P
 252294-66-9P 252294-67-0P 252294-68-1P
 252294-69-2P 252294-70-5P 252294-71-6P
 252294-72-7P 252294-73-8P 252294-74-9P
 252294-75-0P 252294-76-1P 252294-77-2P
 252294-78-3P 252294-79-4P 252294-80-7P
 252294-81-8P 252294-82-9P 252294-89-6P
 252294-90-9P 252294-91-0P 252294-92-1P
 252294-93-2P 252294-94-3P 252294-95-4P
 252294-96-5P 252294-97-6P 252294-98-7P
 252294-99-8P 252295-00-4P 252295-01-5P
 252295-02-6P 252295-03-7P 252295-04-8P
 252295-05-9P 252295-06-0P 252295-07-1P
 252295-08-2P 252295-09-3P 252295-10-6P
 252295-11-7P 252295-12-8P 252295-13-9P
 252295-20-8P 252295-21-9P 252295-22-0P
 252295-23-1P 252295-24-2P 252295-26-4P
 252295-27-5P 252295-28-6P 252295-29-7P
 252295-30-0P 252295-31-1P 252295-32-2P
 252295-33-3P 252295-34-4P 252295-35-5P
 252295-36-6P 252295-37-7P 252295-53-7P
 252295-54-8P 252295-55-9P 252295-56-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)

RN 252279-11-1 CAPLUS

CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-81-2 CAPLUS

CN Carbamic acid, [2-[[2-[[2-((1R)-2-(1H-indol-3-yl)-1-[[spiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-82-3 CAPLUS

CN Carbamic acid, [2-[[2-[[2-((1R)-1-[[2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-83-4 CAPLUS

CN Carbamic acid, [2-[[2-[[2-((1R)-1-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-84-5 CAPLUS

CN Carbamic acid, [2-[[2-[[2-((1R)-1-[[1,4'-bipiperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-85-6 CAPLUS

CN Carbamic acid, [2-[[2-[[2-((1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-86-7 CAPLUS

CN Carbamic acid, [2-[[2-[[2-((1R)-1-[[4-(4-hydroxy-4-phenyl-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-87-8 CAPLUS


CN Carbamic acid, [2-[[2-[[2-((1R)-2-(1H-indol-3-yl)-1-[[4-(phenyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-88-9 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-1-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-89-0 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(2-methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-90-3 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-1-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-91-4 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-92-5 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-93-6 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-94-7 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252292-95-8 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-96-9 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-


methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-97-0 CAPLUS
CN Carbamic acid, (1-[[[(1R)-1-[4-[2-[[2-[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-98-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[[2-[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-01-9 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[2,3-dihydrospiro[1H-inden-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-02-0 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-99-2 CAPLUS
CN Carbamic acid, [2-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-00-8 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[spiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-03-1 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-04-2 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[1,4'-bipiperidin]-1'-ylcarbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-05-3 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-06-4 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[4-(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-07-5 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenyl-1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-08-6 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-09-7 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-[2-(methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-10-0 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-11-1 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-12-2 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-13-3 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-14-4 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-15-5 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252293-16-6 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252293-17-7 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-[[[1,1-dimethylethoxy]carbonyl]amino]


]-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-18-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[[3-[[[1,1-dimethylethoxy]carbonyl]amino]propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-19-9 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-20-2 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[spiro[1H-inden-1,4'-piperidin]-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-21-3 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-1-[[[2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-22-4 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[4-oxo-1-phenyl-1,3,8-triazaaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-23-5 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-24-6 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-1-[[[1,4'-bipiperidin]-1'-ylcarbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-25-7 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-26-8 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-1-[[[4-(hydroxy-4-phenyl-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-27-9 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-(phenyl-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-28-0 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-1-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-29-1 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-[2-(methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-30-4 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-32-6 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-35-9 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-37-1 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-38-2 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252293-39-3 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252293-40-6 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-


methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-41-7 CAPLUS
CN Carbamic acid, [1-[[[[(1R)-1-4-[[2-[[[4-[[[1,1-dimethylethoxy]carbonyl]amino]butyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-42-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[[(1R)-1-4-[[2-[[[4-[[[1,1-dimethylethoxy]carbonyl]amino]butyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-43-9 CAPLUS
CN Carbamic acid, [4-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-44-0 CAPLUS
CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-46-2 CAPLUS
CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[2,3-dihydrospiro[1H-indene-1,4'-piperidine]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252293-47-3 CAPLUS
CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252293-48-4 CAPLUS
CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 252293-49-5 CAPLUS
CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[1,4'-bipiperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-50-8 CAPLUS

CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— OBU-t

RN 252293-51-9 CAPLUS
CN Carbamic acid, [3-[[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-hydroxy-4-phenyl-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-52-0 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenyl-1-piperazinyl)carbonylamino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-53-1 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[4-(2-fluorophenyl)-1-piperazinyl]carbonylamino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-54-2 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(2-(methylthio)phenyl)-1-piperazinyl]carbonylamino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-55-3 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonylamino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252293-56-4 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonylamino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t


RN 252293-57-5 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 252293-58-6 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t


RN 252293-59-7 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 252293-60-0 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-61-1 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-62-2 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[4-[2-[[[3-[[[1,1-dimethylethoxy]carbonyl]amino]methyl]cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t

RN 252293-63-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[1R]-1-[4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]methyl]cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t

RN 252293-64-4 CAPLUS
 CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t


RN 252293-65-5 CAPLUS
 CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-66-6 CAPLUS
 CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-67-7 CAPLUS
 CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-68-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-69-9 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-70-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-71-3 CAPLUS
CN 1(2H)-Pyridinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-72-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-73-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-74-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-75-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-76-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-77-9 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-{2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-78-0 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-{2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-80-4 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, N-((1R)-1-(4-{2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-81-5 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(2-aminoethyl)-2-((1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino)-2-(1H-indol-3-yl)ethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-82-6 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-{2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-83-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-amino-N-((1R)-1-(4-{2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-84-8 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-{2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-85-9 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(2-aminoethyl)-2-((1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino)ethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-86-0 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-((1R)-1-(4-{2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl}-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-87-1 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-88-2 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-89-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-90-6 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-91-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-92-8 CAPLUS
CN 1(2H)-Pyridinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-93-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-94-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-95-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-96-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-97-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-98-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-99-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-00-1 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-01-2 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(3-aminopropyl)-2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-03-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-04-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-amino-N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN 252294-05-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-06-7 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(3-aminopropyl)-2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-07-8 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-08-9 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-09-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-10-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-12-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-14-7 CAPLUS
CN 1(2H)-Pyridinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-16-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-18-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-20-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-22-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-23-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-24-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-25-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-26-1 CAPLUS

CN 1H-Imidazole-4-acetamide, N-(4-aminobutyl)-2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-27-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-28-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-amino-N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.




RN 252294-29-4 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((4-aminobutyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-30-7 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(4-aminobutyl)-2-((1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-31-8 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-32-9 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-33-0 CAPLUS
CN 1,3,8-Triazaaspiro[4.5]decane-8-carboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-34-1 CAPLUS
CN 1-Piperidinecarboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 252294-35-2 CAPLUS
CN 1-Piperidinecarboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-36-3 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-37-4 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 252294-39-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-40-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-41-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-42-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



PAGE 1-B


RN 252294-43-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-44-3 CAPLUS
CN 1H-Imidazole-4-acetamide, N-[[[3-(aminomethyl)cyclohexyl]methyl]-2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-45-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-46-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[(spiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl)amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-47-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[2,3-dihydrospiro{1H-indene-1,4'-piperidin}-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-48-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-oxo-1-phenyl-1,3,8-triazaspiro{4.5}dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-49-8 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-50-1 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[1,4'-bipiperidin]-1'-ylcarbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-51-2 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-52-3 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-53-4 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenyl-1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-54-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-55-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(2-methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-56-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-57-8 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-59-0 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-60-3 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-61-4 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-62-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-63-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-64-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-65-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[(1R)-1-[(1,1-dimethylethoxy)carbonyl]-5-[(phenylmethoxy)carbonyl]amino]pentyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-66-9 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-67-0 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[(2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-68-1 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-6-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-69-2 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-70-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4'-bipiperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-71-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-72-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-(4-hydroxy-4-phenyl-1-piperidyl)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-73-8 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(4-phenyl-1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-74-9 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-75-0 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-76-1 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-77-2 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-78-3 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl] (phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-79-4 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-80-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-81-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[(1R)-5-amino-1-[(1,1-dimethylethoxy)carbonyl]pentyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-82-9 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(piperidinylamino)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-89-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-bromophenyl)-4-[2-[(2-(cyclohexylamino)ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-90-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-bromophenyl)-4-[2-[(2-(butylamino)ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-91-0 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-bromophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-92-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(2-furanylmethyl)amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-93-2 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[[2-[(2-furanylmethyl)amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-94-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[2-(1H-indol-3-yl)ethyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

— OBU-t

RN 252294-95-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[[2-[(2-(1H-indol-3-yl)ethyl]amino]ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252294-96-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(1H-indol-3-yl)ethyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 252294-97-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[3-nitrophenyl]-4-{1,1,13,13-tetramethyl-2,11-


PAGE 1-B

—OBu-t

RN 252294-99-8 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(2-phenylethyl)-4-{1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl]-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252295-00-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(phenylmethyl)-4-{1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl]-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



dioxo-12-oxa-3,6,10-triazatetradec-1-yl]-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252294-98-7 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-{1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl]-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252295-01-5 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl-4-{1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl]-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-02-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-nitrophenyl)-4-{1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl]-1H-imidazol-2-yl]-1,5-pentanediyldiester, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



-OBu-t

RN 252295-03-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[4-(4-chlorophenyl)-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



-OBu-t


RN 252295-04-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(diphenylmethyl)amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-05-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[[2-[(diphenylmethyl)amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-06-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[2-(dimethylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-07-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[2-(2-furanylmethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-08-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[(cyclohexylamino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-09-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[2-(1H-indol-3-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-10-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-(butylamino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-11-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[2-(2-pyridinylethyl)amino]ethyl]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-12-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[3-[[[1,1-dimethylethoxy]carbonyl]amino]propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-13-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(diphenylmethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-20-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-oxo-3-phenylpropyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-21-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(4-bromophenyl)-2-oxoethyl]-4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-22-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


1]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(4-methoxyphenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-23-1 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(4-chlorophenyl)-2-oxoethyl]-4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-24-2 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(3,4-dichlorophenyl)-2-oxoethyl]-4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-26-4 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(1H-imidazol-1-yl)propyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-27-5 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[2-(2-pyridinyl)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-28-6 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(4-morpholinyl)propyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-29-7 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(4-pyridinyl)propyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-30-0 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[2-(diethylamino)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-31-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[[2-(1H-imidazol-1-yl)propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-32-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[[2-(2-pyridinyl)ethyl]amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-33-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-34-4 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(4-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-35-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(diethylamino)ethyl]amino]-1,1-dimethyl-2-


oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-36-6 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[4-(aminocarbonyl)-1-piperidinyl]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-37-7 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-53-7 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-oxo-2-phenylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-54-8 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(2,5-dimethoxyphenyl)-2-oxoethyl]-4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-55-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(4-fluorophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-56-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(4-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252295-57-1P 252295-58-2P 252295-59-3P
252295-61-7P 252295-62-8P 252295-63-9P
252295-64-0P 252295-65-1P 252295-66-2P
252295-67-3P 252295-70-8P 252295-71-9P
252295-72-0P 252295-73-1P 252295-74-2P
252295-75-3P 252295-76-4P 252295-77-5P
252295-78-6P 252295-79-7P 252295-80-0P
252295-81-1P 252295-82-2P 252295-84-4P
252295-85-5P 252295-86-6P 252295-87-7P
252295-88-8P 252295-89-9P 252295-90-2P
252295-91-3P 252295-92-4P 252295-93-5P
252295-94-6P 252295-95-7P 252295-96-8P
252295-97-9P 252295-98-0P 252295-99-1P
252296-00-7P 252296-01-8P 252296-02-9P
252296-03-0P 252296-04-1P 252296-05-2P
252296-06-3P 252296-07-4P 252296-08-5P
252296-09-6P 252296-10-9P 252296-11-0P
252296-12-1P 252296-13-2P 252296-14-3P

252296-15-4P 252296-16-5P 252296-17-6P
 252300-43-9P 252300-44-0P 252300-45-1P
 252300-46-2P 252300-47-3P 252300-48-4P
 252300-49-5P 252300-50-6P 252300-51-7P
 252300-52-0P 252300-53-1P 252300-54-2P
 252300-55-3P 252300-56-4P 252300-57-5P
 252300-58-6P 252301-28-3P 252301-29-4P
 252301-30-7P 252301-32-9P 252301-33-0P
 252301-34-1P 252301-35-2P 252301-36-3P
 252301-37-4P 252301-38-5P 252301-39-6P
 252301-40-9P 252301-41-0P 252301-42-1P
 252301-43-2P 252301-45-4P 252301-68-1P
 252301-69-2P 252306-75-5P 252306-76-6P
 252306-77-7P 252306-78-8P 252306-79-9P
 252306-80-2P 252306-81-3P 252306-82-4P
 252306-83-5P 252308-68-2P 252308-69-3P
 252308-70-6P 252308-71-7P 252308-73-9P
 252308-74-0P 252308-75-1P 252308-76-2P
 252308-77-3P 252308-78-4P 252309-31-2P
 252309-32-3P 252309-33-4P 252309-34-5P
 252309-35-6P 252309-36-7P 252309-37-8P
 252309-38-9P 252309-39-0P 252309-40-3P
 252310-99-9P 252311-00-5P 252311-01-6P
 252311-02-7P 252311-03-8P 252311-04-9P
 252311-05-0P 252311-06-1P 252311-07-2P
 252311-08-3P 252311-09-4P 252311-10-7P
 252311-11-8P 252311-12-9P 252311-14-1P
 252311-15-2P 252311-16-3P 252311-17-4P
 252311-18-5P 252311-19-6P 252311-20-9P
 252311-21-0P 252311-22-1P 252311-23-2P
 252311-24-3P 252311-25-4P 252311-26-5P
 252311-27-6P 252311-28-7P 252311-29-8P
 252311-30-1P 252311-31-2P 252311-32-3P
 252311-33-4P 252311-34-5P 252311-35-6P
 252311-36-7P 252311-82-3P 252311-83-4P
 252311-84-5P 252311-85-6P 252311-86-7P
 252311-87-8P 252311-88-9P 252311-89-0P
 252311-91-4P 252311-92-5P 252311-93-6P
 252311-94-7P 252311-95-8P 252311-96-9P
 252311-97-0P 252311-98-1P 252311-99-2P
 252312-00-8P 252312-02-0P 252312-03-1P
 252312-04-2P 252312-05-3P 252312-06-4P
 252312-07-5P 252312-08-6P 252312-10-0P
 252312-11-1P 252312-12-2P 252312-13-3P
 252312-14-4P 252312-15-5P 252312-16-6P
 252312-17-7P 252312-18-8P 252312-19-9P
 252312-21-3P 252312-22-4P 252312-23-5P
 252312-24-6P 252312-25-7P 252314-51-5P
 252314-52-6P 252314-53-7P 252314-54-8P
 252314-55-9P 252314-56-0P 252314-57-1P
 252314-58-2P 252314-59-3P 252314-60-6P
 252314-61-7P 252314-62-8P 252314-63-9P
 252314-64-0P 252314-65-1P 252314-68-4P
 252314-69-5P 252314-70-8P 252314-71-9P
 252314-72-0P 252314-73-1P 252314-74-2P
 252314-75-3P 252314-76-4P 252314-77-5P
 252314-78-6P 252314-79-7P 252314-80-0P
 252314-81-1P 252314-82-2P 252314-83-3P
 252314-84-4P 252314-85-5P 252314-86-6P
 252315-51-8P 252315-52-9P 252315-53-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)


RN 252295-57-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-{2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(3-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-58-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[2-[4-(diethylamino)phenyl]-2-oxoethyl]-4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-59-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-{2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-oxo-2-(4-(trifluoromethoxy)phenyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-61-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[2-(5-bromo-2-thienyl)-2-oxoethyl]-4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-62-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-{2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-oxo-4-phenylbutyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-63-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[2-(2-benzofuranyl)-2-oxoethyl]-4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-64-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-{2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-oxobutyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-65-1 CAPLUS

CN Carbamic acid, [(1S)-1-[4-{2-[(2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl}-1-[2-oxo-2-(1,2,3,4-tetrahydro-2-oxo-7-quinoliny]ethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-66-2 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-67-3 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-70-8 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(1,2-diethyl-4-pyrazolidinyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-71-9 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-72-0 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(3-(diethylamino)propyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-73-1 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-74-2 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-75-3 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[(2,6-difluorophenyl)methyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-76-4 CAPLUS


CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[2-(4-hydroxyphenyl)ethyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 252295-77-5 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(3,3-diphenylpropyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-78-6 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-79-7 CAPLUS


CN Carbamic acid, [(1S)-1-[4-{1,1-dimethyl-2-[(2-(4-morpholinyl)ethyl]amino)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-80-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(1-phenylmethyl)-4-piperidinylamino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-81-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[(1,2-diethyl-4-pyrazolidinyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-82-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(2-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-84-4 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[(3-(diethylamino)propyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-85-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-86-6 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-87-7 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(dimethylamino)ethyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(1,1-dimethylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-88-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-89-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-90-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-91-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(phenylmethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-92-4 CAPLUS
CN Carbamic acid, [(1S)-1-[(1-benzo[b]thien-3-yl-4-{2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-93-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(4-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-94-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chlorophenyl)-4-{2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


dimethyl-2-oxoethyl]-1-(1,1-dimethylethyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-98-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-99-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(4-chloro-3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-00-7 CAPLUS




RN 252295-95-7 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-96-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-97-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(cyclohexylamino)ethyl]amino]-1,1-


CN Carbamic acid, [(1S)-1-[4-{2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-01-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(phenylmethyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-02-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl-4-{2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252296-03-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-


oxoethyl]-1-(4-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252296-04-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(4-chlorophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-05-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-09-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-10-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252296-11-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


RN 252296-06-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-07-4 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(1,1-dimethylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252296-08-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252296-12-1 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-13-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(4-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-14-3 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chlorophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-15-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(3,4-dichlorophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-16-5 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[1,1-dimethyl-2-oxo-2-[[2-[(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252296-17-6 CAPLUS

CN Carbamic acid, [(1S)-1-[1-(1,1-dimethylethyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252300-43-9 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxo-2-phenylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-44-0 CAPLUS
CN Carbamic acid, [1-[1-(2-[1,1'-biphenyl]-4-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 252300-45-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(2-naphthalenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-46-2 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(4-methoxyphenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-47-3 CAPLUS
CN Carbamic acid, [1-[1-[2-(2,5-dimethoxyphenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252300-48-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-(diethylamino)phenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-49-5 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-chlorophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-50-8 CAPLUS
CN Carbamic acid, [1-[1-[2-(3,4-dichlorophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-51-9 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-chloro-3-methylphenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-52-0 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-bromophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-53-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-54-2 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-cyanophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-55-3 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-azidophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-56-4 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(4-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 252300-57-5 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-(3-nitrophenyl)-2-oxoethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-58-6 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxobutyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252301-29-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 2-A




RN 252301-33-0 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-chloro-3-nitrophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252301-34-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxo-2-(4-(phenylmethoxy)phenyl)ethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 252301-35-2 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(4-pentylphenyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252301-36-3 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(1,2,3,4-tetrahydro-2-

oxo-7-quinolinyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-37-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(5-chloro-3-methylbenzo[b]thien-2-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-38-5 CAPLUS
CN Carbamic acid, [1-[1-[2-(benzo[b]thien-3-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 252301-41-0 CAPLUS
CN Carbamic acid, [1-[1-[2-[3-(2,4-dichlorophenyl)-5-isoxazolyl]-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




RN 252301-39-6 CAPLUS
CN Carbamic acid, [1-[1-[2-(5-bromo-2-thienyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-40-9 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(3-phenyl-5-isoxazolyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252301-42-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(3-(1H-indol-3-yl)-2-oxopropyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-43-2 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxo-4-phenylbutyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-45-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(3,4-difluorophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-68-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-69-2 CAPLUS
CN Ethanimidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI


RN 252306-75-5 CAPLUS
CN Acetamide, 2-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-76-6 CAPLUS
CN Butanamide, 4-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-77-7 CAPLUS
CN Hexanamide, 6-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-78-8 CAPLUS
CN Acetamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 252306-79-9 CAPLUS
CN Benzamide, 4-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-80-2 CAPLUS
CN Propanamide, 5-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 252306-81-3 CAPLUS
CN Pentanamide, 5-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-81-4 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-83-5 CAPLUS
CN Benzeneacetamide, 4-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-66-2 CAPLUS
CN Carbamic acid, [3-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-69-3 CAPLUS
CN Carbamic acid, [2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-70-6 CAPLUS
CN Carbamic acid, [4-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-71-7 CAPLUS
CN Carbamic acid, [6-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-73-9 CAPLUS
CN Carbamic acid, [2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-74-0 CAPLUS
CN Carbamic acid, [4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-75-1 CAPLUS
CN Carbamic acid, [2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-76-2 CAPLUS
CN Carbamic acid, [5-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-77-3 CAPLUS
CN Carbamic acid, [[4-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252308-78-4 CAPLUS
CN Carbamic acid, [4-[2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252309-31-2 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




RN 252309-32-3 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

• HI




● HI

RN 252309-33-4 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-34-5 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-35-6 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-36-7 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-37-8 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-38-9 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-39-0 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-40-3 CAPLUS
CN Ethanimidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-[(1,1-dimethylethyl)sulfonyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI


RN 252310-99-9 CAPLUS
CN 4-Morpholinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-00-5 CAPLUS
CN 3-Thiazolidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-01-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252311-02-7 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-03-8 CAPLUS
CN Urea, N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N-(2-hydroxyethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-04-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 252311-05-0 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 252311-06-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-07-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 252311-08-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 252311-09-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-10-7 CAPLUS
CN Urea, N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-11-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252311-12-9 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 252311-14-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-15-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 252311-16-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-17-4 CAPLUS
CN 1,4-Dioxo-8-azaspiro[4.5]decane-8-carboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-18-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy-4-phenyl- (9CI) (CA INDEX NAME)




RN 252311-19-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 252311-20-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-21-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 252311-22-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252311-23-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 252311-24-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 252311-25-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252311-26-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252311-27-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-28-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 252311-29-8 CAPLUS
CN Benzamide, N-[4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl](phenylmethyl)amino]butyl]- (9CI) (CA INDEX NAME)




RN 252311-30-1 CAPLUS
CN Urea, N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-31-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 252311-32-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-33-4 CAPLUS
CN Urea, N-[2-(dimethylamino)ethyl]-N'-(1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-34-5 CAPLUS
CN Urea, N,N-bis[3-(dimethylamino)propyl]-N'-(1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-35-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 252311-36-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 252311-82-3 CAPLUS
CN Urea, N-[3-(dimethylamino)propyl]-N'-(1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-83-4 CAPLUS
CN Urea, N-cycloheptyl-N'-(1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-84-5 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 252311-85-6 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[4-(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252311-86-7 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-87-8 CAPLUS
CN Urea, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)



RN 252311-88-9 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(4-methoxyphenyl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-89-0 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(3,4,5-trimethoxyphenyl)methyl)- (9CI) (CA INDEX NAME)




RN 252311-91-4 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


yl)ethyl]-N'-(2-(4-nitrophenyl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-92-5 CAPLUS
CN Urea, N-(3,3-dimethylbutyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-93-6 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-94-7 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-95-8 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(3-(4-morpholinyl)propyl)- (9CI) (CA INDEX NAME)




RN 252311-96-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 252311-97-0 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-[(5-nitro-2-pyridinyl)amino]ethyl)- (9CI) (CA INDEX NAME)




RN 252311-98-1 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-[(phenylmethyl)thio]ethyl)- (9CI) (CA INDEX NAME)




RN 252311-99-2 CAPLUS
CN Urea, N-(3,4-dihydroxyphenyl)methyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-00-8 CAPLUS
CN Urea, N-[(1,2-diethyl-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-02-0 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-03-1 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252312-04-2 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-05-3 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-06-4 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-07-5 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-08-6 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-10-0 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-11-1 CAPLUS




RN 252312-12-2 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-13-3 CAPLUS
CN Urea, N-[(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-14-4 CAPLUS
CN Urea, N-[2-(3-chlorophenyl)ethyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-15-5 CAPLUS
CN Urea, N-[2-(4-bromophenyl)ethyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-16-6 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252312-17-7 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 252312-18-8 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-pyridinylmethyl]- (9CI) (CA INDEX NAME)




RN 252312-19-9 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252312-21-3 CAPLUS


CN Urea, N-[(2-chlorophenyl)methyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-22-4 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252312-23-5 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252312-24-6 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252312-25-7 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 252314-51-5 CAPLUS
CN Urea, N-cyclopentyl-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-52-6 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(4-hydroxybutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-53-7 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-54-8 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-55-9 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-56-0 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-57-1 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-58-2 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-59-3 CAPLUS
CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-60-6 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-61-7 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-thienyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-62-8 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-63-9 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-64-0 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-[[2-(hydroxymethyl)phenyl]thio]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-65-1 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-68-4 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-69-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[[[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-70-8 CAPLUS
CN Urea, N-cyclopentyl-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-71-9 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(4-hydroxybutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-72-0 CAPLUS
CN Urea, N-(2,2-diethoxyethyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-73-1 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-74-2 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-75-3 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-76-4 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252314-77-5 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252314-78-6 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)


imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-79-7 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-80-0 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-81-1 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(trifluoromethyl)phenyl)methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-82-2 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-83-3 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-[(2-(hydroxymethyl)phenyl)thio]phenyl)methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-84-4 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-85-5 CAPLUS
CN Benzene sulfonamide, 4-[2-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-86-6 CAPLUS
CN Benzene sulfonamide, 4-[2-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-51-8 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-52-9 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252315-53-0 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252315-54-1P 252315-55-2P 252315-56-3P
252315-57-4P 252315-58-5P 252315-59-6P
252315-60-9P 252315-61-0P 252315-62-1P
252315-63-2P 252315-65-4P 252315-66-5P
252315-67-6P 252315-68-7P 252315-69-8P
252315-70-1P 252315-71-2P 252315-72-3P
252315-73-4P 252315-74-5P 252315-75-6P
252315-76-7P 252315-77-8P 252315-78-9P
252315-79-0P 252315-80-3P 252315-81-4P
252315-83-6P 335242-96-1P 335243-06-6P

335243-44-2P 335243-49-7P 335243-63-5P


335246-48-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)


RN 252315-54-1 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'- (4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-55-2 CAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-56-3 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-57-4 CAPLUS
CN Benzoic acid, 4-[[[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-58-5 CAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-59-6 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-3-nitrophenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-60-9 CAPLUS
CN Benzamide, N-[[[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]thiomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-61-0 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-62-1 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-63-2 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-65-4 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-66-5 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-hexyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-67-6 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-68-7 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-69-8 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-70-1 CAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-71-2 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-72-3 CAPLUS
CN Benzoic acid, 4-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-73-4 CAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-74-5 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-nitrophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-75-6 CAPLUS
CN Thiourea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-76-7 CAPLUS
CN Benzamide, N-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-77-8 CAPLUS
CN Thiourea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-78-9 CAPLUS
CN Thiourea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-79-0 CAPLUS
CN Thiourea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-80-3 CAPLUS
CN Thiourea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-81-4 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-83-6 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335242-96-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-06-6 CAPLUS
CN Carbamic acid, [(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-44-2 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



•x HCl


RN 335243-49-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-63-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




•x HCl

RN 335246-48-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




IT 252315-89-2 335247-36-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)
RN 252315-89-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -[2-[(1S)-1-[[[1,1-dimethylethoxy]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]- α , α -dimethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-36-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252315-89-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)
RN 252315-89-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -[2-[(1S)-1-[[[1,1-dimethylethoxy]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]- α , α -dimethyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:688017 CAPLUS
DOCUMENT NUMBER: 135:370087
TITLE: Different pattern of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma
AUTHOR(S): Brinckmann, J.; Neese, C. M.; Geber, Y.; Sobhi, H.; Notbohm, H.; Hunzelmann, N.; Fietzek, P. P.; Muller, P. K.; Risteli, J.; Gebker, R.; Scharffetter-Kochanek, K.
CORPORATE SOURCE: Department of Dermatology, Medical University of Lubeck, Lubeck, 23552, Germany
SOURCE: Journal of Investigative Dermatology (2001), 117(2), 269-273
CODEN: JIDEAB; ISSN: 0022-202X
PUBLISHER: Blackwell Science, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Changes in the process of crosslinking of collagen mole. are associated with defects in the biomech. stability of the extracellular matrix. Fibrosis of skin is characterized by an increase in pyridinolines, which are hydroxyllysine aldehyde derived cross-links usually absent in healthy skin. In this study, we analyzed cross-links in lipodermatosclerosis and localized scleroderma to address the question whether all the mature cross-links currently characterized are increased in fibrosis in addition to the increase in pyridinolines. As psoralen plus UV A treatment leads to clin. improvement of fibrotic plaques in localized scleroderma we analyzed the cross-link content in lesional skin after bath psoralen plus UV A

therapy. In skin from patients with localized scleroderma an increase in the total number of mature cross-links was found to be due to an increase in both pyridinolines and dehydrohistidinohydroxymerodesmosine. The concentration of histidinohydroxylysinoxonorleucine was unchanged. By contrast, the total number of mature cross-links was decreased in lipodermatosclerosis. This decrease was caused by a decrease of lysine aldehyde derived cross-links (dehydro-histidinohydroxymerodesmosine and histidinohydroxylysinoxonorleucine), whereas the concentration of pyridinolines increased. A decrease in the content of pyridinolines after bath psoralen plus UV A treatment was found in six out of nine patients with localized scleroderma, which might reflect a remodeling of the extracellular matrix. Our data provide evidence that sclerosis of skin is associated with either an increase in the number of cross-links per mol. of collagen or a change in the mol. nature of the cross-links formed.

IT 108212-74-4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(collagen cross-links in lipodermatosclerosis and circumscribed scleroderma in humans treated by UV radiation A and bath psoralen)
RN 108212-74-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -amino-4-(2-amino-2-carboxyethyl)-c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:283789 CAPLUS
DOCUMENT NUMBER: 134:311210
TITLE: 5-Membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments
INVENTOR(S): Chabrier de Lassauniers, Pierre-Etienne; Harnett, Jeremiah; Bigg, Dennis; Pommier, Jacques; Lannoy, Jacques; Liberatore, Anne-Marie; Thurieu, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S., Fr.
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
FR 2799461 A1 20010413 FR 1999-12643 19991011
FR 2799461 B1 20020104
FR 2812546 A1 20020208 FR 2000-10151 20000801
CA 2388505 AA 20010419 CA 2000-2388505 20001010
BR 2000014649 A 20020618 BR 2000-14649 20001010
EP 1223933 A2 20020724 EP 2000-967988 20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
EP 1228760 A2 20020807 EP 2002-76763 20001010
EP 1228760 A3 20040128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2003511416 T2 20030325 JP 2001-529718 20001010
NZ 518304 A 20040730 NZ 2000-518304 20001010
NZ 533429 A 20040924 NZ 2000-533429 20001010
AU 783129 B2 20050929 AU 2000-77965 20001010
EP 1589007 A2 20051026 EP 2005-76749 20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY
RU 2271355 C2 20060310 RU 2002-112227 20001010
NO 2002001689 A 20020530 NO 2002-1689 20020410
US 2004132788 A1 20040708 US 2003-681002 20031008
US 2005038087 A1 20050217 US 2004-915001 20040810

PRIORITY APPLN. INFO.:
FR 1999-12643 A 19991011
FR 2000-10151 A 20000801
FR 2000-11169 A 20000901
EP 2000-967988 A3 20001010
EP 2002-76763 A3 20001010
WO 2000-FR2805 W 20001010
FR 2001-4943 A 20010410
FR 2002-1811 A 20020214
US 2002-89993 A2 20020404
WO 2002-FR1218 A1 20020409
US 2003-681002 A2 20031008

OTHER SOURCE(S): MARPAT 134:311210
OI



AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-Q [I; wherein the substituted heterocyclic ring Het(A)(B) = Q¹-Q⁴; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S;

n = 0-6; R₁, R₂ = especially H, alkyl, or cycloalkyl; Q = NR₃R₄ or OR₅; R₃ and R₄ = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl or (cycloalkyl)alkoxyalkyl; R₅ = H, alkyl, alkynyl, or cyanoalkyl. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P285)2 in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and selenification (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex preps., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.

IT 335242-96-1P, (1R)-N-Benzyl-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine 335243-06-6P, (1R)-tert-Butyl [1-(4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl]carbamate 335243-44-2P, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-49-7P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine 335243-63-5P, (1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethylamine hydrochloride


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of five-membered heterocycle derive. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 335242-96-1 CAPLUS

CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-06-6 CAPLUS


CN Carbamic acid, [(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-44-2 CAPLUS

CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl

RN 335243-49-7 CAPLUS

CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-63-5 CAPLUS

CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



•x HCl


IT 252279-11-1, (1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethylamine 335246-48-5, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (drug candidate; preparation of five-membered heterocycle derive. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 252279-11-1 CAPLUS


CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-48-5 CAPLUS

CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




IT 335247-36-4, (1R)-1-(1-Benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine

RL: RCT (Reactant); RACT (Reactant or reagent) (precursor; preparation of five-membered heterocycle derive. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 335247-36-4 CAPLUS

CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:23838 CAPLUS

DOCUMENT NUMBER: 135:59560

TITLE: An increase of mature type skin collagen cross-link, histidinohydroxylysinoxonoleucine, in the sclerotic skin of morphea

AUTHOR(S): Tamura, M.; Ishikawa, O.

CORPORATE SOURCE: Department of Dermatology, Gunma University School of Medicine, Gunma, Maebashi, Showa-machi, 371-8511, Japan

SOURCE: Journal of Dermatological Science (2001), 25(1), 83-86

CODEN: JDSERI; ISSN: 0923-1811

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histidinohydroxylysinoxonoleucine (HHL) is a trivalent cross-link of type I collagen that is stable and has physiol. properties. In this study, we conducted a biochem. quantification of HHL in 5 patients with morphea. We compared the quantity of HHL contained in the lesional skin and the adjacent normal skin. The molar ratio of HHL to collagen in the sclerotic lesion was significantly higher than that of the adjacent normal skin (0.36±0.09 vs. 0.28±0.10, P<0.01). We could find no relationship between an increase of HHL content and the duration of the disease. The results indicate that an increased amount of HHL may play a certain role to inducing the sclerotic skin change characteristic of morphea.


IT 108212-74-4

RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(mature type skin collagen cross-link, histidinohydroxylysinoxonoleucine, increased in the sclerotic skin of morphea)

RN 108212-74-4 CAPLUS

CN 1H-Imidazole-2-hexanoic acid, α-amino-4-[(2-amino-2-carboxyethyl)-
ε-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:908619 CAPLUS

DOCUMENT NUMBER: 134:248860

TITLE: Effects of singlet oxygen on the extracellular matrix
protein collagen: Oxidation of the collagen crosslink
histidinohydroxylysine and histidine

AUTHOR(S): Au, Van; Madison, Stephen A.

CORPORATE SOURCE: Skin Biophysics and Delivery, Unilever Research U.S.,
Edgewater, NJ, 07020, USA

SOURCE: Archives of Biochemistry and Biophysics (2000),
384(1), 133-142

CODEN: ABBIA4; ISSN: 0003-9861

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The reaction of singlet oxygen, a putative agent of skin photodamage, with
the dermal collagen crosslink histidinohydroxylysine (HHL) and
its precursor histidine is reported. Reaction studies were performed with
both purified HHL and bovine dermal tissue. We demonstrate that singlet
oxygen can selectively oxidize HHL and histidine amino acid residues in
dermal tissue and that intermediate oxidation products of histidine lead to
new crosslink products. A novel mechanism for crosslink formation was
proposed to involve nucleophilic addition to a transient imidazolone
intermediate formed from singlet oxygen oxidation of the histidine imidazole
moiety. The implication for such adduct formation and histidine oxidation in
collagen proteins is the expression of aberrant collagen crosslinks,
perturbation of the dermal collagen function, and hence an altered dermal
state. (c) 2000 Academic Press.

IT 330814-55-6


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(singlet oxygen effects on extracellular matrix collagen:
histidinohydroxylysine and histidine oxidation)

RN 330814-55-6 CAPLUS

CN 1H-Imidazole-2-hexanoic acid, α-amino-ε-[(5-amino-5-carboxy-
2-hydroxypentyl)amino]-4-[(5)-aminocarboxymethyl]-, (αS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:391139 CAPLUS

DOCUMENT NUMBER: 133:129526

TITLE: Computer prediction of biological activity spectra for
low-molecular peptides and peptidomimetics

AUTHOR(S): Martynova, N. B.; Filimonov, D. A.; Poroikov, V. V.

CORPORATE SOURCE: Institute of Biomedical Chemistry, Russian Academy of
Medical Sciences, Moscow, 119832, Russia

SOURCE: Russian Journal of Bioorganic Chemistry (Translation
of Bioorganicheskaya Khimiya) (2000), 26(5), 297-305

CODEN: RJBCEJ; ISSN: 1068-1620

PUBLISHER: MAIK Nauka/Interperiodica

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The wide variety of the biol. effects of peptides and their high activity
are the main reasons for the search for new basic drug structures among
them. The most promising compds. can be selected using the PASS computer
system (Prediction of Activity Spectra for Substances). This system was
originally developed to predict the activities of low-mol. "drug-like"
organic compds. Its predictive capacity is described here by the example of
134 peptides and peptidomimetics with nine known biol. activities. Its
average predictive power is shown to be approx. 97%. Such an accuracy
demonstrates that computer prediction can be applied both to the
evaluation of effects and mechanisms of action of endogenous and synthetic
peptides and to the screening of new therapeutic agents among the most
promising basic structures.

IT 168468-58-4 168468-74-4 168468-80-2

168468-84-6 172922-37-1 172922-38-2

172922-39-3


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)

(endothelin receptor antagonist; computer prediction of biol. activity
spectra for low-mol. peptides and peptidomimetics)

RN 168468-58-4 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-
[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-
1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-74-4 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-
[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-
methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-80-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-
[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-
1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-84-6 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-
[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-
methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-37-1 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-
[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-
3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-38-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-
[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-
1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-39-3 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2R)-2-[(2-cyclohexylamino)-2-
oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-
methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:795813 CAPLUS

DOCUMENT NUMBER: 132:35702

TITLE: Preparation of imidazolyl- β -carbolines and related compounds as somatostatin receptor mediators and sodium channel blockers.

INVENTOR(S): Thirieau, Christophe Alain; Poitout, Lydie Francine; Gálcerá, Marie-odile; Moinet, Christophe Philippe; Gordon, Thomas D.; Morgan, Barry A.; Bigg, Dennis C. H.; Pommier, Jacques

PATENT ASSIGNEE(S): Societe De Conseil De Recherches Et D'applications Scientifiques S. A., Fr.

SOURCE: PCT Int. Appl., 107 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964420	A1	19991216	WO 1999-US12874	19990608
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ER, ES, FI, GB, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2335339	AA	19991216	CA 1999-2335339	19990608
AU 9945536	A1	19991230	AU 1999-45536	19990608
AU 761020	B2	20030529		
EP 1086101	A1	20010328	EP 1999-928479	19990608
EP 1086101	B1	20021218		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002517500	T2	20020618	JP 2000-553429	19990608
AT 229954	E	20030115	AT 1999-928479	19990608
ES 2188184	T3	20030616	ES 1999-928479	19990608
NZ 508765	A	20031031	NZ 1999-508765	19990608
RU 2233841	C2	20040810	RU 2001-101433	19990608
NO 200006268	A	20010129	NO 2000-6268	20001211
NO 319532	B1	20050829		
HK 1032049	A1	20030417	HK 2001-102432	20010404
US 6586445	B1	20030701	US 2001-719455	20010613
US 2004038970	A1	20040226	US 2003-383949	20030307
PRIORITY APPL. INFO.:			US 1998-89180P	P 19980612

US 1998-97297 A1 19980612
WO 1999-US12874 W 19990608
US 2001-719455 A3 20010613

OTHER SOURCE(S): MARPAT 132:35702
GI




AB Title compds. [1; dotted lines = optional double bonds; X = N, NR4; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, (CH2)mOZ1, etc.; Z1 = (substituted) alkyl, benzothienyl, Ph, naphthyl, benzofuryl, thienyl, indolyl, etc.; R2 = alkyl, ACO2Z5, (substituted) Ph, etc.; Z5 = H, alkyl, aryl, aralkyl; R3 = H; R4 = CYNX1X2, COX2, X2; Y = O, S; X2 = (CH2)mY1X3; X3 = H, (substituted) alkyl, cycloalkyl, alkoxy, aryloxy, alkylamino, Ph, etc.; Y1 = O, S, NH, bond; R5 = alkyl, cycloalkyl, (substituted) Ph, furyl, thienyl, pyrrolyl, pyridinyl, etc.; R6 = H, PhSO2; R7 = H, alkyl, alkoxyalkyl, dialkylaminoalkyl; X1 = H, Cl, F, Br, iodo, NO2, OH, CF3, alkyl, etc.; m = 0-6; n = 1-5], were prepared as drugs (no data). Thus, 2-[1(8)-amino-2-(3-indolyl)ethyl]-4-phenyl-1H-imidazole in CHCl3 was treated with p-anisaldehyde and CF3CO2H followed by 2 days stirring to give a residue which was stirred overnight with aminomethylpolystyrene resin in THF to give 78% 1,2,3,4-tetrahydro-1(RS)-(4-methoxyphenyl)-3(S)-(4-phenyl-1H-imidazol-2-yl)-9H-pyrido[3,4-b]indole.

IT 252278-88-9 252278-89-0 252278-91-4
252278-93-6 252278-95-8 252278-97-0
252278-98-1 252279-00-8 252279-02-0
252279-03-1 252279-04-2 252279-05-3
252279-06-4 252279-07-5 252279-10-0
252279-11-1 252279-37-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl- β -carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)


RN 252278-88-9 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 252278-89-0 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-(1,2-diethyl-4-pyrazolidinyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 252278-91-4 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252278-93-6 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(diethylamino)propyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 252278-95-8 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252278-97-0 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(4-hydroxyphenyl)ethyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 252278-98-1 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-(3,3-diphenylpropyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 252279-00-8 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 252279-02-0 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 252279-03-1 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-[(2,6-difluorophenyl)methyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 252279-04-2 CAPLUS


CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(1H-imidazol-1-yl)propyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 252279-05-3 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-
α,α-dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 252279-06-4 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-
α,α-dimethyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 252279-07-5 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-N-[2-(diethylamino)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 252279-10-0 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-11-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-37-1 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-
α,α-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:795794 CAPLUS
DOCUMENT NUMBER: 132:35701
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors
INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Gálcerá, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moinet, Christophe Philippe
PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications Scientifiques, S.A., Fr.
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964401	A2	19991216	WO 1999-US12760	19990608
WO 9964401	A3	20030417		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2334945	AA	19991216	CA 1999-2334945	19990608
AU 9944257	A1	19991230	AU 1999-44257	19990608
AU 746963	B2	20020509		
EP 1086086	A1	20010128	EP 1999-927323	19990608
EP 1086086	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003523921	T2	20030812	JP 2000-553410	19990608

AT 279396 E 20041015 AT 1999-927323 19990608
PT 1086086 T 20050228 PT 1999-927323 19990608
ES 2229718 T3 20050416 ES 1999-927323 19990608
RU 2263111 C2 20051027 RU 2001-101429 19990608
NO 2000006267 A 20010207 NO 2000-6267 20001211
HK 1031873 A1 20050304 HK 2001-102404 20010403
US 6852725 B1 20050208 US 2001-719457 20010613
US 2004176379 A1 20040909 US 2004-771725 20040204
US 1998-89087P P 19980612
US 1998-96431 A1 19980612
WO 1999-US12760 W 19990608
US 2001-719457 A3 20010613

PRIORITY APPLN. INFO.: MARPAT 132:35701

OTHER SOURCE(S): GI
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo(b)thiophene, Ph, naphthyl, etc.; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mA1; A1 = C(Y)NX1X2; C(Y)X2; C(NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.; m = 0-6] which are useful as agonists or antagonists of somatostatin receptors (no data), and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addition of 2-[(1S)-1-amino-2-(indol-3-yl)ethyl]-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.

IT 252315-86-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

RN 252315-86-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252292-81-2P 252292-82-3P 252292-83-4P
252292-84-5P 252292-85-6P 252292-86-7P
252292-87-8P 252292-88-9P 252292-89-0P
252292-90-3P 252292-91-4P 252292-92-5P
252292-93-6P 252292-94-7P 252292-95-8P

252292-96-9P 252292-97-0P 252292-98-1P
252292-99-2P 252293-00-8P 252293-01-9P
252293-02-0P 252293-03-1P 252293-04-2P
252293-05-3P 252293-06-4P 252293-07-5P
252293-08-6P 252293-09-7P 252293-10-0P
252293-11-1P 252293-12-2P 252293-13-3P
252293-14-4P 252293-15-5P 252293-16-6P
252293-17-7P 252293-18-8P 252293-19-9P
252293-20-2P 252293-21-3P 252293-22-4P
252293-23-5P 252293-24-6P 252293-25-7P
252293-26-8P 252293-27-9P 252293-28-0P
252293-29-1P 252293-30-4P 252293-32-6P
252293-35-9P 252293-37-1P 252293-38-2P
252293-39-3P 252293-40-6P 252293-41-7P
252293-42-8P 252293-43-9P 252293-44-0P
252293-46-2P 252293-47-3P 252293-48-4P
252293-49-5P 252293-50-8P 252293-51-9P
252293-52-0P 252293-53-1P 252293-54-2P
252293-55-3P 252293-56-4P 252293-57-5P
252293-58-6P 252293-59-7P 252293-60-0P
252293-61-1P 252293-62-2P 252293-63-3P
252293-64-4P 252293-65-5P 252293-66-6P
252293-67-7P 252293-68-8P 252293-69-9P
252293-70-2P 252293-71-3P 252293-72-4P
252293-73-5P 252293-74-6P 252293-75-7P
252293-76-8P 252293-77-9P 252293-78-0P
252293-80-4P 252293-81-5P 252293-82-6P
252293-83-7P 252293-84-8P 252293-85-9P
252293-86-0P 252293-87-1P 252293-88-2P
252293-89-3P 252293-90-6P 252293-91-7P
252293-92-8P 252293-93-9P 252293-94-0P
252293-95-1P 252293-96-2P 252293-97-3P
252293-98-4P 252293-99-5P 252294-00-1P
252294-01-2P 252294-03-4P 252294-04-5P
252294-05-6P 252294-06-7P 252294-07-8P
252294-08-9P 252294-09-0P 252294-10-3P
252294-12-5P 252294-14-7P 252294-16-9P
252294-18-1P 252294-20-5P 252294-22-7P
252294-23-8P 252294-24-9P 252294-25-0P
252294-26-1P 252294-27-2P 252294-28-3P
252294-29-4P 252294-30-7P 252294-31-8P
252294-32-9P 252294-33-0P 252294-34-1P
252294-35-2P 252294-36-3P 252294-37-4P
252294-39-6P 252294-40-9P 252294-41-0P
252294-42-1P 252294-43-2P 252294-44-3P
252294-45-4P 252294-46-5P 252294-47-6P
252294-48-7P 252294-49-8P 252294-50-1P
252294-51-2P 252294-52-3P 252294-53-4P
252294-54-5P 252294-55-6P 252294-56-7P
252294-57-8P 252294-59-0P 252294-60-3P
252294-61-4P 252294-62-5P 252294-63-6P
252294-64-7P 252294-65-8P 252294-66-9P
252294-67-0P 252294-68-1P 252294-69-2P
252294-70-5P 252294-71-6P 252294-72-7P
252294-73-8P 252294-74-9P 252294-75-0P
252294-76-1P 252294-77-2P 252294-78-3P
252294-79-4P 252294-80-7P 252294-81-8P
252294-82-9P 252294-89-6P 252294-90-9P
252294-91-0P 252294-92-1P 252294-93-2P
252294-94-3P 252294-95-4P 252294-96-5P
252294-97-6P 252294-98-7P 252294-99-8P
252295-00-4P 252295-01-5P 252295-02-6P
252295-03-7P 252295-04-8P 252295-05-9P
252295-06-0P 252295-07-1P 252295-08-2P
252295-09-3P 252295-10-6P 252295-11-7P


252295-12-8P 252295-13-9P 252295-20-8P
 252295-21-9P 252295-22-0P 252295-23-1P
 252295-24-2P 252295-26-4P 252295-27-5P
 252295-28-6P 252295-29-7P 252295-30-0P
 252295-31-1P 252295-32-2P 252295-33-3P
 252295-34-4P 252295-35-5P 252295-36-6P
 252295-37-7P 252295-53-7P 252295-54-8P
 252295-55-9P 252295-56-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of imidazolyl derive. as as agonists or antagonists of somatostatin receptors)

RN 252292-81-2 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[spiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-82-3 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-1-[[[2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-85-6 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperidiny]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-86-7 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-1-[[[4-(4-hydroxy-4-phenyl-1-piperidiny]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-83-4 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidiny]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-84-5 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-1-[[[1,4'-bipiperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-87-8 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-88-9 CAPLUS


CN Carbamic acid, [2-[[2-[[2-[(1R)-1-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-89-0 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[4-(2-methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-90-3 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-1-[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-91-4 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-92-5 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-1-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-93-6 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-1-[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-94-7 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-2-(1H-indol-3-yl)-1-[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-95-8 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252292-96-9 CAPLUS
CN Carbamic acid, [2-[[2-[[2-[[1R]-1-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252292-97-0 CAPLUS
CN Carbamic acid, [1-[[[1R]-1-[4-[2-[[2-[[1,1-dimethylethoxy]carbonyl]amino


[ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-98-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[1R]-1-[4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-99-2 CAPLUS
CN Carbamic acid, [2-[[[2-[2-[[1R]-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-00-8 CAPLUS
CN Carbamic acid, [3-[[[2-[2-[[1R]-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidin-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-01-9 CAPLUS
CN Carbamic acid, [3-[[[2-[2-[[1R]-1-[[[2,3-dihydrospiro[1H-inden-1,4'-piperidin-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-02-0 CAPLUS
CN Carbamic acid, [3-[[[2-[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-oxo-1-phenyl-1,3,6-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-03-1 CAPLUS
CN Carbamic acid, [3-[[[2-[2-[[1R]-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-04-2 CAPLUS
CN Carbamic acid, [3-[[[2-[2-[[1R]-1-[[[1,4'-bipiperidin-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-05-3 CAPLUS
CN Carbamic acid, [3-[[[2-[2-[[1R]-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-06-4 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(hydroxy-4-phenyl-1-piperidinyl)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-07-5 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenyl-1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-08-6 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-09-7 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(2-methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-10-0 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-11-1 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-12-2 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-13-3 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-14-4 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252293-15-5 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252293-16-6 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-17-7 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-1-[[[4-[[[1,1-dimethylethoxy]carbonyl]amino]-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-18-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[[3-[[[1,1-dimethylethoxy]carbonyl]amino]propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-19-9 CAPLUS
CN Carbamic acid, [3-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-20-2 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[spiro[1H-inden-1,4'-piperidin]-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-21-3 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-1-[[[2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-22-4 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-oxo-1-phenyl-1,3,6-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-23-5 CAPLUS
 CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-24-6 CAPLUS
 CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-25-7 CAPLUS
 CN Carbamic acid, [4-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-26-8 CAPLUS
 CN Carbamic acid, [4-[[2-[[2-[(1R)-1-[[[4-(hydroxy-4-phenyl-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252293-27-9 CAPLUS
 CN Carbamic acid, [4-[[2-[[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenyl-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 252293-32-6 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-35-9 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-37-1 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-38-2 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-39-3 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252293-40-6 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252293-41-7 CAPLUS
CN Carbamic acid, [1-[[[[(1R)-1-[4-[2-[[[4-[[[1,1-dimethylethoxy]carbonyl]amino]butyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


[butyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-42-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[[(1R)-1-[4-[2-[[[4-[[[1,1-dimethylethoxy]carbonyl]amino]butyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-43-9 CAPLUS
CN Carbamic acid, [4-[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-44-0 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[spiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-46-2 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[2,3-dihydrospiro[1H-indene-1,4'-piperidine]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-47-3 CAPLUS

PAGE 1-B



RN 252293-49-5 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[[1,4'-bipiperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-50-8 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252293-48-4 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A




PAGE 1-B

-OBu-t

RN 252293-51-9 CAPLUS
CN Carbamic acid, [[3-[[[2-[2-[(1R)-1-[[4-(hydroxy-4-phenyl-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-52-0 CAPLUS
CN Carbamic acid, [[3-[[[2-[[2-((1R)-2-(1H-indol-3-yl)-1-[[4-(phenyl-1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-53-1 CAPLUS
CN Carbamic acid, [[3-[[[2-[[2-((1R)-1-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-54-2 CAPLUS
CN Carbamic acid, [[3-[[[2-[[2-((1R)-2-(1H-indol-3-yl)-1-[[4-(2-(methylthio)phenyl]-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-55-3 CAPLUS
CN Carbamic acid, [[3-[[[2-[[2-((1R)-1-[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-56-4 CAPLUS

CN Carbamic acid, [[3-[[[2-[[2-((1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t


RN 252293-57-5 CAPLUS
CN Carbamic acid, [[3-[[[2-(2-{{1R}}-1-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 252293-58-6 CAPLUS
CN Carbamic acid, [[3-[[[2-(2-{{1R}}-1-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t


RN 252293-59-7 CAPLUS
CN Carbamic acid, [[3-[[[2-(2-{{1R}}-2-(1H-indol-3-yl)-1-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 252293-60-0 CAPLUS
CN Carbamic acid, [[3-[[[2-(2-{{1R}}-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-61-1 CAPLUS
CN Carbamic acid, [[3-[[[2-(2-{{1R}}-1-[[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252293-62-2 CAPLUS
CN Carbamic acid, [1-[[[{{1R}}-1-[4-[2-[[[3-[[[1,1-dimethylethoxy]carbonyl]amino]methyl]cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t

RN 252293-63-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t

RN 252293-64-4 CAPLUS
 CN Carbamic acid, [[3-[[[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t


RN 252293-65-5 CAPLUS
 CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-66-6 CAPLUS
 CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-67-7 CAPLUS
 CN 1,3,8-Triaza-spiro[4.5]decane-8-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-68-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-69-9 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-70-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-71-3 CAPLUS
CN 1(2H)-Pyridinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-72-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-73-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-74-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-75-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-76-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(2-aminoethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-77-9 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((2-aminoethyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-78-0 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((2-aminoethyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-80-4 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, N-((1R)-1-(4-[2-((2-aminoethyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-81-5 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(2-aminoethyl)-2-((1R)-1-(((2-(dimethylamino)ethyl)(phenylmethyl)amino)carbonyl)amino)-2-(1H-indol-3-yl)ethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-82-6 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((2-aminoethyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-83-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-amino-N-((1R)-1-(4-[2-((2-aminoethyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-84-8 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((2-aminoethyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-85-9 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(2-aminoethyl)-2-((1R)-2-(1H-indol-3-yl)-1-(((1-(phenylmethyl)-4-piperidinyl)amino)carbonyl)amino)ethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-86-0 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-((1R)-1-(4-[2-((3-aminopropyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-87-1 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-88-2 CAPLUS
CN 1,3,8-TriazaSpiro[4.5]decane-8-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-89-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-90-6 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-91-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-92-8 CAPLUS
CN 1(2H)-Pyridinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-93-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-94-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-95-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-96-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-97-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-98-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252293-99-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-00-1 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-01-2 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(3-aminopropyl)-2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-03-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-04-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-amino-N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN 252294-05-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(3-aminopropyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-06-7 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(3-aminopropyl)-2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-07-8 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-08-9 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-09-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-10-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-12-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-14-7 CAPLUS
CN 1(2H)-Pyridinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-16-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-18-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-20-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-22-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-23-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-24-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-25-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-26-1 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(4-aminobutyl)-2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-27-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252294-28-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-amino-N-[(1R)-1-[4-[2-[(4-aminobutyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.




RN 252294-29-4 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((4-aminobutyl)amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-30-7 CAPLUS
CN 1H-Imidazole-4-acetamide, N-(4-aminobutyl)-2-((1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-31-8 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-32-9 CAPLUS
CN Spiro[1H-indene-1,4'-piperidine]-1'-carboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-33-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252294-34-1 CAPLUS
CN 1-Piperidinecarboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 252294-35-2 CAPLUS
CN 1-Piperidinecarboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-36-3 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-37-4 CAPLUS
CN 1-Piperazinecarboxamide, N-((1R)-1-(4-[2-((3-(aminomethyl)cyclohexyl)methyl)amino]-1,1-dimethyl-2-oxoethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-39-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-(methylthio)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-40-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-41-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-42-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 252294-43-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-44-3 CAPLUS
CN 1H-Imidazole-4-acetamide, N-[[[3-(aminomethyl)cyclohexyl]methyl]-2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-alpha,alpha-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-45-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-1-[4-[2-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-46-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[(spiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl)amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-47-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-48-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-49-8 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-50-1 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[1,4'-bipiperidin]-1'-ylcarbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-51-2 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-52-3 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(hydroxy-4-phenyl-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-53-4 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenyl-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-54-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-55-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(2-(methylthio)phenyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-56-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-57-8 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-59-0 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-60-3 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-61-4 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-62-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-63-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-64-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-65-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[(1R)-1-[(1,1-dimethylethoxy)carbonyl]-5-[(phenylmethoxy)carbonyl]amino]pentyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-66-9 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-N6-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-67-0 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[(2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-68-1 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-69-2 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-70-5 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[1,4'-bipiperidin]-1'-yl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-71-6 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-72-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-73-8 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[4-(4-phenyl-1-piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-74-9 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-75-0 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[1-(piperazinyl)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-76-1 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-77-2 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-78-3 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-79-4 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-80-7 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-1-[[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-81-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-1-[4-[2-[(1R)-5-amino-1-[(1,1-dimethylethoxy)carbonyl]pentyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-82-9 CAPLUS
CN D-Lysine, N2-[2-[2-[(1R)-2-(1H-indol-3-yl)-1-[(4-piperidinylamino)carbonyl]amino]ethyl]-1H-imidazol-4-yl]-2-methyl-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-89-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-bromophenyl)-4-[2-[(2-(cyclohexylamino)ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-90-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-bromophenyl)-4-[2-[(2-(butylamino)ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-91-0 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-bromophenyl)-4-[1,1-dimethyl-2-oxo-2-[(2-[(2-pyridinyl)ethyl]amino)ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-92-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[(2-[(2-furanylmethyl)amino]ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252294-93-2 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[(2-[(2-furanylmethyl)amino]ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252294-94-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[(2-[(2-(1H-indol-3-yl)ethyl]amino)ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

OBu-t

RN 252294-95-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[(2-[(2-(1H-indol-3-yl)ethyl]amino)ethyl]amino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252294-96-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-{2-[[2-[[2-(1H-indol-3-yl)ethyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OBu-t

RN 252294-97-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(3-nitrophenyl)-4-(1,1,13,13-tetramethyl-2,11-

dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252294-98-7 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252294-99-8 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(2-phenylethyl)-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252295-00-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(phenylmethyl)-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 252295-01-5 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-02-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-nitrophenyl)-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentanediyldiester], bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



-OBu-t

RN 252295-03-7 CAPLUS
 CN Carbamic acid, [(18)-1-[1-(4-chlorophenyl)-4-(1,1,13,13-tetramethyl-2,11-dioxo-12-oxa-3,6,10-triazatetradec-1-yl)-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



-OBu-t


RN 252295-04-8 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[2-[(diphenylmethyl)amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-05-9 CAPLUS
 CN Carbamic acid, [(18)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[[2-[(diphenylmethyl)amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-06-0 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[2-(dimethylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-07-1 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[2-(furan-2-ylmethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-08-2 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-(cyclohexylamino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-09-3 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[2-(1H-indol-3-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-10-6 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-(butylamino)-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-11-7 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[2-(pyridin-2-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-12-8 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[3-[[[1,1-dimethylethoxy]carbonyl]amino]propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-13-9 CAPLUS
 CN Carbamic acid, [(18)-1-[4-[2-[[2-[[2-[(diphenylmethyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentenediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-20-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-oxo-3-phenylpropyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-21-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(4-bromophenyl)-2-oxoethyl]-4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-22-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


1]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(4-methoxyphenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-23-1 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(4-chlorophenyl)-2-oxoethyl]-4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-24-2 CAPLUS
CN Carbamic acid, [(1S)-1-[1-[2-(3,4-dichlorophenyl)-2-oxoethyl]-4-[2-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-26-4 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(1H-imidazol-1-yl)propyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-27-5 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(1H-imidazol-1-yl)propyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-28-6 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-29-7 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[3-(1H-imidazol-1-yl)propyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-30-0 CAPLUS
CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-[2-(diethylamino)ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-31-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[[3-(1H-imidazol-1-yl)propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-32-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-(2-pyridinyl)ethyl]amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-33-3 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-34-4 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(4-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-35-5 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[2-[[2-(diethylamino)ethyl]amino]-1,1-dimethyl-2-

oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-36-6 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[2-[4-(aminocarbonyl)-1-piperidinyl]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-37-7 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-53-7 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-oxo-2-phenylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-54-8 CAPLUS

CN Carbamic acid, [(1S)-1-[1-[2-(2,5-dimethoxyphenyl)-2-oxoethyl]-4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-55-9 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(4-fluorophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-56-0 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(4-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252295-57-1P 252295-58-2P 252295-59-3P
252295-61-7P 252295-62-8P 252295-63-9P
252295-64-0P 252295-65-1P 252295-66-2P
252295-67-3P 252295-70-8P 252295-71-9P
252295-72-0P 252295-73-1P 252295-74-2P
252295-75-3P 252295-76-4P 252295-77-5P
252295-78-6P 252295-79-7P 252295-80-0P
252295-81-1P 252295-82-2P 252295-84-4P
252295-85-5P 252295-86-6P 252295-87-7P
252295-88-8P 252295-89-9P 252295-90-2P
252295-91-3P 252295-92-4P 252295-93-5P
252295-94-6P 252295-95-7P 252295-96-8P
252295-97-9P 252295-98-0P 252295-99-1P
252296-00-7P 252296-01-8P 252296-02-9P
252296-03-0P 252296-04-1P 252296-05-2P
252296-06-3P 252296-07-4P 252296-08-5P
252296-09-6P 252296-10-9P 252296-11-0P
252296-12-1P 252296-13-2P 252296-14-3P

252296-15-4P 252296-16-5P 252296-17-6P
 252300-43-9P 252300-44-0P 252300-45-1P
 252300-46-2P 252300-47-3P 252300-48-4P
 252300-49-5P 252300-50-6P 252300-51-7P
 252300-52-0P 252300-53-1P 252300-54-2P
 252300-55-3P 252300-56-4P 252300-57-5P
 252300-58-6P 252301-28-3P 252301-29-4P
 252301-30-7P 252301-32-9P 252301-33-0P
 252301-34-1P 252301-35-2P 252301-36-3P
 252301-37-4P 252301-38-5P 252301-39-6P
 252301-40-9P 252301-41-0P 252301-42-1P
 252301-43-2P 252301-45-4P 252301-68-1P
 252301-69-2P 252306-75-5P 252306-76-6P
 252306-77-7P 252306-78-8P 252306-79-9P
 252306-80-2P 252306-81-3P 252306-82-4P
 252306-83-5P 252308-68-2P 252308-69-3P
 252308-70-6P 252308-71-7P 252308-73-9P
 252308-74-0P 252308-75-1P 252308-76-2P
 252308-77-3P 252308-78-4P 252309-31-2P
 252309-32-3P 252309-33-4P 252309-34-5P
 252309-35-6P 252309-36-7P 252309-37-8P
 252309-38-9P 252309-39-0P 252309-40-3P
 252310-99-9P 252311-00-5P 252311-01-6P
 252311-02-7P 252311-03-8P 252311-04-9P
 252311-05-0P 252311-06-1P 252311-07-2P
 252311-08-3P 252311-09-4P 252311-10-7P
 252311-11-0P 252311-12-9P 252311-14-1P
 252311-15-2P 252311-16-3P 252311-17-4P
 252311-18-5P 252311-19-6P 252311-20-9P
 252311-21-0P 252311-22-1P 252311-23-2P
 252311-24-3P 252311-25-4P 252311-26-5P
 252311-27-6P 252311-28-7P 252311-29-8P
 252311-30-1P 252311-31-2P 252311-32-3P
 252311-33-4P 252311-34-5P 252311-35-6P
 252311-36-7P 252311-82-3P 252311-83-4P
 252311-84-5P 252311-85-6P 252311-86-7P
 252311-87-8P 252311-88-9P 252311-89-0P
 252311-91-4P 252311-92-5P 252311-93-6P
 252311-94-7P 252311-95-8P 252311-96-9P
 252311-97-0P 252311-98-1P 252311-99-2P
 252312-00-8P 252312-02-0P 252312-03-1P
 252312-04-2P 252312-05-3P 252312-06-4P
 252312-07-5P 252312-08-6P 252312-10-0P
 252312-11-1P 252312-12-2P 252312-13-3P
 252312-14-4P 252312-15-5P 252312-16-6P
 252312-17-7P 252312-18-8P 252312-19-9P
 252312-21-3P 252312-22-4P 252312-23-5P
 252312-24-6P 252312-25-7P 252314-51-5P
 252314-52-6P 252314-53-7P 252314-54-8P
 252314-55-9P 252314-56-0P 252314-57-1P
 252314-58-2P 252314-59-3P 252314-60-6P
 252314-61-7P 252314-62-8P 252314-63-9P
 252314-64-0P 252314-65-1P 252314-68-4P
 252314-69-5P 252314-70-8P 252314-71-9P
 252314-72-0P 252314-73-1P 252314-74-2P
 252314-75-3P 252314-76-4P 252314-77-5P
 252314-78-6P 252314-79-7P 252314-80-0P
 252314-81-1P 252314-82-2P 252314-83-3P
 252314-84-4P 252314-85-5P 252314-86-6P
 252315-51-8P 252315-52-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazolyl deriva. as as agonists or antagonists of somatostatin receptors)


RN 252295-57-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-(3-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-58-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[2-[4-(diethylamino)phenyl]-2-oxoethyl]-4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-59-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-oxo-2-(4-(trifluoromethoxy)phenyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-61-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[2-(5-bromo-2-thienyl)-2-oxoethyl]-4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-62-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-oxo-4-phenylbutyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-63-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[1-[2-(2-benzofuranyl)-2-oxoethyl]-4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-64-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-oxobutyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-65-1 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[2-[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-[2-oxo-2-(1,2,3,4-tetrahydro-2-oxo-7-quinolinyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-66-2 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-67-3 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-70-8 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(1,2-diethyl-4-pyrazolidinyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-71-9 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-72-0 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(3-(diethylamino)propyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-73-1 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-74-2 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-75-3 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(2,6-difluorophenyl)methyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-76-4 CAPLUS


CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(2-(4-hydroxyphenyl)ethyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 252295-77-5 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-N-(3,3-diphenylpropyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-78-6 CAPLUS

CN 1H-Imidazole-4-acetamide, 2-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-79-7 CAPLUS


CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-80-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(1-phenylmethyl)-4-piperidinylamino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-81-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[(1,2-diethyl-4-pyrazolidinyl)amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-82-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(2-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-84-4 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[3-(diethylamino)propyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-85-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-86-6 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-87-7 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(dimethylamino)ethyl]amino]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(1,1-dimethylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-88-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-89-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-90-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-91-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(phenylmethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-92-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl-4-[2-[[3-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-93-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(4-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-94-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chlorophenyl)-4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


dimethyl-2-oxoethyl]-1-(1,1-dimethylethyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-98-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252295-99-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(4-chloro-3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-00-7 CAPLUS




RN 252295-95-7 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252295-96-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252295-97-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(cyclohexylamino)ethyl]amino]-1,1-


CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-01-8 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(phenylmethyl)-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-02-9 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl-4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1H-imidazol-2-yl]-1,5-pentanediyldis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252296-03-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-


oxoethyl]-1-(4-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-04-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(4-chlorophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-05-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-09-6 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chloro-3-nitrophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-10-9 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(2-phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252296-11-0 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(phenylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


RN 252296-06-3 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-07-4 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[2-[[2-(butylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-1-(1,1-dimethylethyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252296-08-5 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(3-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252296-12-1 CAPLUS
CN Carbamic acid, [(1S)-1-[1-benzo[b]thien-3-yl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-13-2 CAPLUS
CN Carbamic acid, [(1S)-1-[4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1-(4-nitrophenyl)-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-14-3 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(4-chlorophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanediy]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252296-15-4 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(3,4-dichlorophenyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252296-16-5 CAPLUS
CN Carbamic acid, [(1S)-1-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252296-17-6 CAPLUS

CN Carbamic acid, [(1S)-1-[1-(1,1-dimethylethyl)-4-[1,1-dimethyl-2-oxo-2-[[2-[[2-(2-pyridinyl)ethyl]amino]ethyl]amino]ethyl]-1H-imidazol-2-yl]-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252300-43-9 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxo-2-phenylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-44-0 CAPLUS
CN Carbamic acid, [1-[1-(2-(1,1'-biphenyl)-4-yl-2-oxoethyl)-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 252300-45-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-(2-naphthalenyl)-2-oxoethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-46-2 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 252300-47-3 CAPLUS
CN Carbamic acid, [1-[1-[2-(2,5-dimethoxyphenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-48-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-(diethylamino)phenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-49-5 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-chlorophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-50-8 CAPLUS
CN Carbamic acid, [1-[1-[2-(3,4-dichlorophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-51-9 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-chloro-3-methylphenyl)-2-oxoethyl]-4-(1,1-

dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-52-0 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-bromophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-53-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-54-2 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-cyanophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-55-3 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-azidophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252300-56-4 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(4-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 252300-57-5 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(3-nitrophenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252300-58-6 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxobutyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 252301-28-3 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-(4-(trifluoromethoxy)phenyl)-2-oxoethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252301-29-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 2-A





RN 252301-33-0 CAPLUS
CN Carbamic acid, [1-[1-[2-(4-chloro-3-nitrophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 252301-30-7 CAPLUS
CN Carbamic acid, [1-[1-[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-32-9 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




RN 252301-34-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(4-(phenylmethoxy)phenyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252301-35-2 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(4-pentylphenyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 252301-36-3 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(1,2,3,4-tetrahydro-2-

oxo-7-quinolinyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-37-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(5-chloro-3-methylbenzo[b]thien-2-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-38-5 CAPLUS
CN Carbamic acid, [1-[1-(2-benzo[b]thien-3-yl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 252301-41-0 CAPLUS
CN Carbamic acid, [1-[1-[2-[3-(2,4-dichlorophenyl)-5-isoxazolyl]-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




RN 252301-39-6 CAPLUS
CN Carbamic acid, [1-[1-[2-(5-bromo-2-thienyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-40-9 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[2-oxo-2-(3-phenyl-5-isoxazolyl)ethyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252301-42-1 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-[3-(1H-indol-3-yl)-2-oxopropyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-43-2 CAPLUS
CN Carbamic acid, [1-[4-(1,1-dimethylethyl)-1-(2-oxo-4-phenylbutyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-45-4 CAPLUS
CN Carbamic acid, [1-[1-[2-(3,4-difluorophenyl)-2-oxoethyl]-4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-68-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI


RN 252301-69-2 CAPLUS
CN Ethanimidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

● HI


RN 252306-75-5 CAPLUS
CN Acetamide, 2-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-76-6 CAPLUS
CN Butanamide, 4-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-77-7 CAPLUS
CN Hexanamide, 6-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-78-8 CAPLUS
CN Acetamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 252306-79-9 CAPLUS
CN Benzamide, 4-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-80-2 CAPLUS
CN Propanamide, 2-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 252306-81-3 CAPLUS
CN Pentanamide, 5-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-82-4 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252306-83-5 CAPLUS
CN Benzeneacetamide, 4-amino-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-66-2 CAPLUS
CN Carbamic acid, [3-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-69-3 CAPLUS
CN Carbamic acid, [2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-70-6 CAPLUS
CN Carbamic acid, [4-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-71-7 CAPLUS
CN Carbamic acid, [6-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-73-9 CAPLUS
CN Carbamic acid, [2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-74-0 CAPLUS
CN Carbamic acid, [4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-75-1 CAPLUS
CN Carbamic acid, [2-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-76-2 CAPLUS
CN Carbamic acid, [5-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-77-3 CAPLUS
CN Carbamic acid, [[4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-78-4 CAPLUS
CN Carbamic acid, [4-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252309-31-2 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




RN 252309-32-3 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-33-4 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-34-5 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-35-6 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-36-7 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-37-8 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-38-9 CAPLUS
CN Benzenecarboximidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-39-0 CAPLUS
CN Benzeneethanimidamide, 2,6-dichloro-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-40-3 CAPLUS
CN Ethanimidamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-[(1,1-dimethylethyl)sulfonyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI


RN 252310-99-9 CAPLUS
CN 4-Morpholinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-00-5 CAPLUS
CN 3-Thiazolidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-01-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252311-02-7 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-03-8 CAPLUS
CN Urea, N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N-(2-hydroxyethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-04-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 252311-05-0 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 252311-06-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-07-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 252311-08-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 252311-09-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-10-7 CAPLUS
CN Urea, N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-11-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252311-12-9 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 252311-14-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-15-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 252311-16-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-17-4 CAPLUS
CN 1,4-Dioxo-8-azaspiro[4.5]decane-8-carboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-18-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy-4-phenyl- (9CI) (CA INDEX NAME)




RN 252311-19-6 CAPLUS
CN beta-Alanine, N-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 252311-20-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-21-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 252311-22-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252311-23-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 252311-24-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 252311-25-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252311-26-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252311-27-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-28-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 252311-29-8 CAPLUS
CN Benzamide, N-[4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl](phenylmethyl)amino]butyl]- (9CI) (CA INDEX NAME)




RN 252311-30-1 CAPLUS
CN Urea, N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-31-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 252311-32-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-33-4 CAPLUS
CN Urea, N-[2-(dimethylamino)ethyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-34-5 CAPLUS
CN Urea, N,N-bis[3-(dimethylamino)propyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-35-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 252311-36-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 252311-82-3 CAPLUS
CN Urea, N-[3-(dimethylamino)propyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-83-4 CAPLUS
CN Urea, N-cycloheptyl-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-84-5 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 252311-85-6 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252311-86-7 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-87-8 CAPLUS
CN Urea, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252311-88-9 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(1H-imidazol-4-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-89-0 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(3,4,5-trimethoxyphenyl)methyl)- (9CI) (CA INDEX NAME)




RN 252311-91-4 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(4-(1,1-dimethylethyl)-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl)- (9CI) (CA INDEX NAME)


yl)ethyl]-N'-(2-(4-nitrophenyl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-92-5 CAPLUS
CN Urea, N-(3,3-dimethylbutyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252311-93-6 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252311-94-7 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 252311-95-8 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(3-(4-morpholinyl)propyl)- (9CI) (CA INDEX NAME)




RN 252311-96-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 252311-97-0 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-[[5-nitro-2-pyridinyl]amino]ethyl)- (9CI) (CA INDEX NAME)




RN 252311-98-1 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-[[phenylmethyl]thio]ethyl)- (9CI) (CA INDEX NAME)




RN 252311-99-2 CAPLUS
CN Urea, N-[(3,4-dihydroxyphenyl)methyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-00-8 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-02-0 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-03-1 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-04-2 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-05-3 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-06-4 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-07-5 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252312-08-6 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-10-0 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-11-1 CAPLUS


CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-12-2 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-13-3 CAPLUS
CN Urea, N-[(1,2-dihydro-4-pyrazolidinyl)-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-14-4 CAPLUS
CN Urea, N-[2-(3-chlorophenyl)ethyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-15-5 CAPLUS
CN Urea, N-[2-(4-bromophenyl)ethyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-16-6 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252312-17-7 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 252312-18-8 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-pyridinylmethyl]- (9CI) (CA INDEX NAME)




RN 252312-19-9 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252312-21-3 CAPLUS


CN Urea, N-[2-(chlorophenyl)methyl]-N'-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252312-22-4 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252312-23-5 CAPLUS
CN Urea, N-[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)



RN 252312-24-6 CAPLUS
CN Urea, N-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252312-25-7 CAPLUS
CN Urea, N-[[1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 252314-51-5 CAPLUS
CN Urea, N-cyclopentyl-N'-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-52-6 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(4-hydroxybutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-53-7 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-54-8 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-55-9 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-56-0 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-57-1 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[1-naphthalenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-58-2 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-59-3 CAPLUS
CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-60-6 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-61-7 CAPLUS
CN Urea, N-[[1R]-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-thienylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-62-8 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(trifluoromethyl)phenyl]methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-63-9 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-chlorophenyl)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-64-0 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(4-chlorophenyl)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-65-1 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(2-diphenylethyl)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-68-4 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(1H-imidazol-1-yl)propyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-69-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[[[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-70-8 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-71-9 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-72-0 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-73-1 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-74-2 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-75-3 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-76-4 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252314-77-5 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252314-78-6 CAPLUS
CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-79-7 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-80-0 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-81-1 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-82-2 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-83-3 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[[2-[[2-(hydroxymethyl)phenyl]thio]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-84-4 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-85-5 CAPLUS
CN Benzene sulfonamide, 4-[2-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-86-6 CAPLUS
CN Benzene sulfonamide, 4-[2-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-51-8 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252315-52-9 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252315-53-0P 252315-54-1P 252315-55-2P
252315-56-3P 252315-57-4P 252315-58-5P
252315-59-6P 252315-60-9P 252315-61-0P
252315-62-1P 252315-63-2P 252315-65-4P
252315-66-5P 252315-67-6P 252315-68-7P
252315-69-8P 252315-70-1P 252315-71-2P
252315-72-3P 252315-73-4P 252315-74-5P
252315-75-6P 252315-76-7P 252315-77-8P
252315-78-9P 252315-79-0P 252315-80-3P
252315-81-4P 252315-83-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolyl deriva. as as agonists or antagonists of somatostatin receptors)


RN 252315-53-0 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-54-1 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-55-2 CAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-56-3 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-57-4 CAPLUS
CN Benzoic acid, 4-[[[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonyl]amino)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-58-5 CAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-59-6 CAPLUS
CN Urea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-60-9 CAPLUS
CN Benzamide, N-[[[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]thiomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-61-0 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-62-1 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-63-2 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-65-4 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-66-5 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-hexyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-67-6 CAPLUS
CN Thiourea, N-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-68-7 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-69-8 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-70-1 CAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-71-2 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-72-3 CAPLUS
CN Benzoic acid, 4-[[[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino]carbonylamino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-73-4 CAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-74-5 CAPLUS
CN Urea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-75-6 CAPLUS
CN Thiourea, N-[(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-76-7 CAPLUS
CN Benzamide, N-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]amino)thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-77-8 CAPLUS
CN Thiourea, N-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-78-9 CAPLUS
CN Thiourea, N-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-79-0 CAPLUS
CN Thiourea, N-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-(4-(phenylmethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-80-3 CAPLUS
CN Thiourea, N-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-81-4 CAPLUS
CN Thiourea, N-[(3-chlorophenyl)-N'-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-83-6 CAPLUS
CN Thiourea, N-[(1,3-benzodioxol-5-ylmethyl)-N'-([(1S)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252315-89-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as as agonists or antagonists of somatostatin receptors)
RN 252315-89-2 CAPLUS
CN 1H-imidazole-4-acetic acid, 2-[(1S)-1-[(1,1-dimethylethoxy)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 252315-88-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as as agonists or antagonists of somatostatin receptors)

RN 252315-88-1 CAPLUS
CN 1H-imidazole-4-acetic acid, 2-[(1S)-1-[(1,1-dimethylethoxy)carbonyl]amino]-2-(1H-indol-3-yl)ethyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L11 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:793862 CAPLUS
DOCUMENT NUMBER: 130:119078
TITLE: Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs
AUTHOR(S): Raevsky, Oleg A.; Schaper, Klaus-Jurgen
CORPORATE SOURCE: Laboratory of Computer-Aided Molecular Design, Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia
SOURCE: European Journal of Medicinal Chemistry (1998), 33(10), 799-807
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The H-bond donor and acceptor descriptors Σ cd and ECa, which are estimated directly from thermodyn. data of hydrogen bonding, were successfully used for the correlation with permeability and absorption data for some chems. and drugs. The evaluation of different types of permeability test systems and of different classes of compds. showed that in addition to steric bulk effects both the H-bond donor and acceptor strength play an important role in explaining differences in permeability and absorption of neutral chemical compds. and drugs. However, because of the frequently observed intercorrelation between Σ cd and ECa, often only the more significant of them leads to a significant regression coefficient in multiple linear regression equations. In comparison with ICD and/or ECa less significant correlations are obtained with the exptl. parameter Δ logP (the difference between the octanol/water partition coefficient logPOct and logP for the system alkane or cyclohexane/water) which has to be considered as a composed descriptor containing H-bond donor as well as H-bond acceptor effects.
IT 219959-69-0 219959-71-4 219959-72-5
219959-73-6 219959-74-7 219959-75-8
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(quant. estimation of H-bond contribution to permeability and absorption processes of chems. and drugs)
RN 219959-69-0 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[(1S)-1-[(cyclohexylamino)methyl]amino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 219959-71-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylmethylamino)methyl]amino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-(9CI) (CA INDEX NAME)




RN 219959-72-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexyloxy)methyl]amino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 219959-73-6 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylamino)methyl]methylamino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-9CI) (CA INDEX NAME)



RN 219959-74-7 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylamino)methoxy]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 219959-75-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[2-(cyclohexylamino)ethyl]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:575182 CAPLUS
DOCUMENT NUMBER: 129:286635
TITLE: Altered posttranslational modifications of collagen in
keloid
AUTHOR(S): Uzawa, Katsuhiko; Marshall, Melanie K.; Katz, Elton
P.; Tanzawa, Hideki; Yeowell, Heather N.; Yamauchi,
Mitsuo
CORPORATE SOURCE: CB# 7455 Dental Research Center, The University of


SOURCE: North Carolina at Chapel Hill, Chapel Hill, NC,
27599-7455, USA
Biochemical and Biophysical Research Communications
(1998), 249(3), 652-655
CODEN: BBRCA9; ISSN: 0006-291X

PUBLISHER:	Academic Press
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Keloid is a tissue with an excessive accumulation of collagen. In this study, we have partially characterized post-translational modifications of type I collagen in human keloid in order to pursue their potential involvement in this pathol. The levels of lysyl hydroxylation of the helical portions of $\alpha 1$ and $\alpha 2$ chains of type I collagen in keloid were significantly higher than those of normal, while the levels of prolyl hydroxylation were identical between these two groups. The contents of the major reducible crosslinks in dermal collagen, dehydro-hydroxylysineonorleucine and dehydro-histidinohydroxymers-desmosine, were both significantly higher in keloids (up to sixfold) than those of normal. In addition, significant amts. of hydroxylysine-aldehyde derived crosslinks that are characteristic of skeletal tissue collagens, dehydro-dihydroxylysineonorleucine (about 0.3 mol/mol of collagen) and pyridinoline (about 0.1 mol/mol of collagen), were found in keloids. These results indicate that keloid-forming cells are phenotypically different from those in normal dermis and that the collagen produced is highly crosslinked. The increased crosslinking provides the fibrils with more stability that may result in an accumulation of collagen. (c) 1998 Academic Press.

IT 108212-74-4
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence);
BSU (Biological study, unclassified); BIOL (Biological study); OCCU
(Occurrence)

RN	108212-74-4	CAPLUS
CN	1H-Imidazole-2-hexanoic acid, α -amino-4-(2-amino-2-carboxyethyl)- ϵ -[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)	



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:681307 CAPLUS
DOCUMENT NUMBER: 127:356714
TITLE: Measurement of histidinohydroxylysine in collagen by reversed-phase
hydroxyproline in skin collagen by reversed-phase
high-performance liquid chromatography after
9-fluorenylmethyl chloroformate labeling
AUTHOR(S): Kondo, Asami; Ishikawa, Osamu; Okada, Katsuyuki;
Miyachi, Yoshiki; Abe, Shuzo; Kuboki, Yoshinori
CORPORATE SOURCE: Department of Dermatology, Gunma University School of
Medicine, Maebashi, 371, Japan
SOURCE: Analytical Biochemistry (1997), 252(2), 255-259
CODEN: ANBCA2; ISSN: 0003-2697
PUBLISHER: Academic
DOCUMENT TYPE: Journal

LANGUAGE: English

AB A novel, highly sensitive method to quantify histidinohydroxylysine in collagen, was developed. HHL in skin hydrolyzates labeled with 9-fluorenylmethyl chloroformate (FMOC-Cl) was separated by reversed-phase HPLC. Mass spectrometric anal. revealed that two FMOCs were bound to two primary amino acid residues, histidine and hydroxylysine, but not to lysine residue in one HHL mol. Hydroxyproline was simultaneously measured to express the molar ratio of HHL to collagen. The detection range of HHL was from 1 to 10 pmol and that of hydroxyproline from 1 to 50 pmol. A 6-mm punch-biopsied human skin sample contained 0.40 to 0.69 mol of HHL per one mol. of collagen. This sensitive method is useful as it is rapid and can be used to examine the aging process or the change of HHL content in skin collagens of various pathol. states.

IT 198646-11-6

RL: ANT (Analyte); ANST (Analytical study)


(determination of histidinohydroxylysine and hydroxyproline in

skin collagen by reversed-phase HPLC after 9-fluorenylmethyl chloroformate labeling)

RN 198646-11-6 CAPLUS

CN 1H-Imidazole-2-hexanoic acid, α -amino-4-[(5-amino-5-carboxy-2-hydroxypentyl)amino]-4-(aminocarbonylmethyl)-, [5S,6S,7S]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:243318 CAPLUS

DOCUMENT NUMBER: 126:260958

TITLE: Histidinohydroxylysine in human dermis of sun-exposed and sun-protected sites determined by high-performance liquid chromatography

AUTHOR(S): Okada, Katsuyuki; Kondo, Asami; Ishikawa, Osamu; Miyachi, Yoshiki; Kuboki, Yoshinori

CORPORATE SOURCE: Department of Dermatology, Gunma University School of Medicine, Maebashi, 371, Japan

SOURCE: Photomedicine and Photobiology (1996), 18, 79-80

CODEN: PHPHEA; ISSN: 0912-232X

PUBLISHER: Japanese Society for Photomedicine and Photobiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A novel method using high-performance liquid chromatog. to analyze histidinohydroxylysine in collagen, was established. This method is more sensitive and easier than amino acid anal. for the measurement of HHL at picomole order. The HHL content decreased in sun-exposed skin as compared with sun-protected skin of the aged individuals (n=3). It is suggested that UV light may decrease the HHL content in the dermis.


IT 108212-74-4

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(histidinohydroxylysine in human dermis of sun-exposed and sun-protected sites determined by HPLC)

RN 108212-74-4 CAPLUS

CN 1H-Imidazole-2-hexanoic acid, α -amino-4-[(2-amino-2-carboxyethyl)-c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)



L11 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:180115 CAPLUS

DOCUMENT NUMBER: 126:275846

TITLE: Biomechanical and biochemical study of a standardized wound healing model

AUTHOR(S): Paul, R. G.; Tarlton, J. P.; Purslow, P. P.; Sims, T. J.; Watkins, P.; Marshall, P.; Ferguson, M. J.; Bailey, A. J.

CORPORATE SOURCE: Collagen Research Group, University of Bristol, Bristol, BS18 7DY, UK

SOURCE: International Journal of Biochemistry & Cell Biology (1997), 29(1), 211-220

CODEN: IJBBFU; ISSN: 1357-2725

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Standardized protocols were developed for use in a detailed investigation into the biomech. and biochem. properties of a dermal wound healing model in the rat. The use of a rapid freezing method at -80° minimized the detrimental effects of freezing on the biomech. properties of the tissue and also allowed for convenient inter-laboratory collaboration to be performed. The methodol. described allowed for the simultaneous and reproducible measurement of tensile strength, collagen crosslinking and proteolytic enzyme activity. Increases in the tensile properties of the tissue with time were consistent with an active process of remodelling process as indicated by changes in the cross-link and enzyme profiles. Initially the granulation tissue was comparatively rich in the keto-imine cross-link hydroxylysino-keto-norleucine, which was later replaced by the aldime cross-link dehydro-hydroxylysine. The mature cross-link histidino-hydroxy-lysine was not observed within the granulation tissue at any stage and was also absent in aged control skin. A peak of matrix metalloproteinase-9 activity was observed at early time-points (48 h) and then decreased rapidly to normal levels and is consistent with an acute inflammatory response. In contrast matrix metalloproteinase-2 activity peaked later (3 days) and then decreased gradually, consistent with its role as one of the predominant enzymes involved in the remodelling process. The results described validate the animal model used and emphasize its potential for use in combined biomech. and biochem. studies of acute wound healing.

IT 108212-74-4

RL: BOC (Biological occurrence); BSU (Biological study, unclassified);


BIOL (Biological study); OCCU (Occurrence)

(tensile strength, collagen crosslinking, and proteolytic enzymes in

standardized wound healing model)

RN 108212-74-4 CAPLUS

CN 1H-Imidazole-2-hexanoic acid, α -amino-4-[(2-amino-2-carboxyethyl)-c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:462297 CAPLUS

DOCUMENT NUMBER: 125:143312

TITLE: Preparation of ((acylamino)(indolyl)ethyl)azolecarboxylates and related compounds as endothelin antagonists.

INVENTOR(S): Von Geldern, Thomas; Kester, Jeffrey A.; Tasker, Andrew S.; Sorensen, Brian K.; Rosenberg, Saul H.; Hutchins, Charles W.; Winn, Martin

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611927	A1	19960425	WO 1995-US13373	19951010
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1994-322114	A 19941012
			US 1995-442124	A 19950530
OTHER SOURCE(S):			MARPAT 125:143312	
GI				



AB Title compds. [I; X = imino, O, S; Q = O, (substituted) methylene; R1 = alkyl, cycloalkyl, aralkyl aralkenyl, aryloxy, amino, spirocarboxycyl, spiroheterocycyl, etc.; E = (substituted) alkyl; G = H, alkyl; Ar = aryl, bicyclic aryl, bicyclic heteroaryl; Y = H, (substituted) alkyl, cycloalkyl, aryl, aralkyl; Z = acyl, cyano, OH, tetrazolyl, OH, alkoxy, sulfonamido, specified heterocycyl, etc.], were prepared Thus, title compound (II), prepared by solution phase couplings, at 1 μ M inhibited [125I]ET-1 binding to endothelin A receptors by 81.2%.

IT 172922-38-2P 172922-39-3P 179169-17-6P

179169-18-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of ((acylamino)(indolyl)ethyl)azolecarboxylates and related

compds. as endothelin antagonists)

RN 172922-38-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172922-39-3 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2R)-2-[2-(cyclohexylamino)-2-


oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179169-17-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylmethylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179169-18-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(methylphenylamino)carbonyl]oxy]-1-oxopentyl]amino]ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 168470-61-9P 168470-62-0P 179169-34-7P
179169-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compds. as endothelin antagonists)


RN 168470-61-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-62-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-amino-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179169-34-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[2-(cyclohexylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179169-36-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:73848 CAPLUS

DOCUMENT NUMBER: 124:193276

TITLE: Azole Endothelin Antagonists. 2. Structure-Activity Studies

AUTHOR(S): von Geldern, Thomas W.; Kester, Jeffrey A.; Bal, Radhika; Wu-Wong, Jinsyun R.; Chiou, William; Dixon, Douglas B.; Opgenorth, Terry J.
CORPORATE SOURCE: Pharmaceutical Products Research, Abbott Laboratories, Abbott Park, IL, 60064, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(4), 968-81
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:193276

AB Structure-activity studies have been performed to improve the potency of a novel series of azole-based endothelin-A (ETA) selective antagonists. Modifications of the hydrophobic group on the terminal urea produced substantial effects on receptor affinity; in particular, the choice of cyclohexyl- or arylureas led to substantial improvements in activity. Conformational restriction of these groups provides an addnl. benefit. N-Methylation of the indole moiety which is part of the heterocyclic dipeptide surrogate also improves potency. The effects of these two modifications appear to be synergistic, with the best of the resultant doubly modified analogs exhibiting an 80-200-fold improvement over the original leads.


IT 168470-58-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of azole peptide endothelin antagonists in relation to structure)

RN 168470-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 168468-13-1P 168468-58-4P 168468-60-8P
168468-70-0P 168468-72-2P 168468-82-4P
174063-59-3P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(preparation of azole peptide endothelin antagonists in relation to structure)


RN 168468-13-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[[1R)-1-[[2S)-2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-3-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-60-8 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[bicyclo[2.2.1]hept-2-ylamino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, (9CI) (CA INDEX NAME)




RN 168468-70-0 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[cyclopentylamino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-72-2 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[cycloheptylamino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-82-4 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[phenylamino]carbonyl]amino]pentyl]amino]ethyl]-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-59-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[3-methylcyclohexyl]amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1 α(R*(S*))],3β]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 168468-15-3P 168468-30-2P 168468-31-3P
168468-33-5P 168468-37-9P 168468-41-5P
168468-62-0P 168468-68-6P 168468-75-5P
173962-20-4P 174063-51-5P 174063-52-6P
174063-56-0P 174063-57-1P 174063-58-2P

174063-60-6P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of azole peptide endothelin antagonists in relation to structure)


RN 168468-15-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-30-2 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-1,5-dimethyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-31-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-1-(phenylmethyl)-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-33-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[cyclohexylamino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-37-9 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]sulfonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-41-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[phenylmethyl]amino]carbonyl]amino]pentyl]amino]ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

[S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-62-0 CAPLUS


CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [1(R)-[1 α(R*)],4β]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-68-6 CAPLUS


CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(4-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 168468-75-5 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-ethyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173962-20-4 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(diethylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174063-51-5 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1R-[1 α(S*(R*))],2α]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174063-52-6 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1 α(R*(S*))],3α]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174063-56-0 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1R-[1 α(S*(R*))],2β]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174063-57-1 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1 α(R*(S*))],2α]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174063-58-2 CAPLUS

CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1 α(R*(S*))],2β]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174063-60-6 CAPLUS


CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1R-[1 α(S*(R*))],3β]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 168470-54-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of azole peptide endothelin antagonists in relation to structure)
 RN 168470-54-0 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[2-((1H-indol-3-yl)-1-[[[phenylmethoxy]carbonyl]amino]ethyl)-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:73847 CAPLUS
 DOCUMENT NUMBER: 124:164291
 TITLE: Azole Endothelin Antagonists. 1. A Receptor Model Explains an Unusual Structure-Activity Profile
 AUTHOR(S): von Geldern, Thomas W.; Hutchins, Charles; Kester, Jeffrey A.; Wu-Wong, Jinshyun R.; Chiou, William; Dixon, Douglas B.; Opgenorth, Terry J.
 CORPORATE SOURCE: Pharmaceutical Products Research Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
 SOURCE: Journal of Medicinal Chemistry (1996), 39(4), 957-67
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:164291
 AB The pseudotetrapeptide FR-139317 is a potent and highly selective antagonist of the endothelin-A (ETA) receptor; however, its peptidic nature leads to poor oral absorption characteristics which make it an unlikely drug candidate. To improve these properties, the authors have replaced a portion of the amide bond framework of FR-139317 with a heterocyclic surrogate. The resultant analogs are also ETA-selective

antagonists, but show a structure-activity profile substantially different from that of the peptidic series, particularly with regard to the requirements for the side chain group that has been incorporated into the heterocycle. The nature of the heterocycle itself also has profound effects on the activity of the compds. Both of these surprising results can be rationalized through examination of a 3D model of ET ligand-receptor binding that has previously been developed in the authors labs.


IT 168470-54-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of azole peptide endothelin antagonists in relation to receptor model explaining unusual structure-activity profile)
 RN 168470-54-0 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[2-((1H-indol-3-yl)-1-[[[phenylmethoxy]carbonyl]amino]ethyl)-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 168468-13-1P 168468-16-4P 168468-18-6P
 168468-20-0P 168468-22-2P 168468-24-4P
 168468-26-6P
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (preparation of azole peptide endothelin antagonists in relation to receptor model explaining unusual structure-activity profile)
 RN 168468-13-1 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-5-methyl-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-16-4 CAPLUS


CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-5-phenyl-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-18-6 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-5-(phenylmethyl)-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-20-0 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 5-ethyl-2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-22-2 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-


yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-5-propyl-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-24-4 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-5-(1-methylethyl)-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-26-6 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 5-cyclopropyl-2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-((1H-indol-3-yl)ethyl)-, (S-(R*,S*))]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 1996:73845 CAPLUS

DOCUMENT NUMBER: 124:127005

TITLE: Azole Endothelin Antagonists. 3. Using $\Delta \log P$

as a Tool To Improve Absorption

AUTHOR(S): von Geldern, Thomas W.; Hoffman, Daniel J.; Kester, Jeffrey A.; Nellans, Hugh N.; Dayton, Brian D.; Calzadilla, Samuel V.; Marsh, Kennan C.; Hernandez, Lisa; Chiou, William; et al.

CORPORATE SOURCE: Pharmaceutical Products Research Division, Abbott Laboratories, Abbott Park, IL, 60064, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(4), 982-91


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The oral absorption profile of a family of azole-based ETA-selective antagonists has been improved through a rational series of structural modifications which were suggested by anal. of the physicochem. parameter $\Delta \log P$. Comparison of urea I with a series of well-absorbed compds. using $\Delta \log P$ anal. suggested that I has an excess capacity for forming hydrogen bonds with solvent. A series of urea modifications were explored as a means of reducing H-bonding capacity while maintaining affinity for the ETA-receptor. The correlation between $\Delta \log P$ values and absorption in an intraduodenal (id) bioavailability model was good; this strategy uncovered replacements for each of the urea NH groups which simultaneously improve both potency and drug absorption. A combination of these optimized modifications produces a carbamate which is a highly-selective ETA antagonist with a potency/bioavailability profile consistent with an oral route of administration.


IT 168468-58-4P 168468-74-4P 168468-80-2P
168468-84-6P 172922-37-1P 172922-38-2P
172922-39-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(azole endothelin antagonists: using $\Delta \log P$ as a tool to improve absorption)

RN 168468-58-4 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-74-4 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-80-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168468-84-6 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-37-1 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-38-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2S)-2-[[[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-39-3 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[(2R)-2-[2-(cyclohexylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 172922-29-1P 172922-45-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(azole endothelin antagonists: using $\Delta \log P$ as a tool to improve absorption)

RN 172922-29-1 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[[(phenylmethoxy)carbonyl]amino]ethyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172922-45-1 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:020329 CAPLUS
DOCUMENT NUMBER: 123:257412
TITLE: Preparation of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates and related compounds as endothelin antagonists.
INVENTOR(S): Vongeldern, Thomas W.; Kester, Jeffrey A.; Rosenberg, Saul H.; Winn, Martin; Hutchins, Charles W.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9508550	A1	19950330	WO 1994-US10049	19940907

W: CA, JP
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1993-126822 A 19930924
US 1994-295441 A 19940829
OTHER SOURCE(S): MARPAT 123:257412
GI



AB Title compds. [I; m = 0-2; X = NR2, O, S; R2 = H, alkyl, aralkyl, heterocyclylalkyl; Q = RIANS, Q1; A = CO, SO2; R1 = alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, cycloalkylamino, heterocyclyl, heterocyclylamino, spirocarbocyclyl, spiroheterocyclyl, etc.; B = H, alkyl; R20 = alkyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, spirocarbocyclyl, spiroheterocyclyl; r = 2-4; E = (substituted) alkyl; G = H, alkyl; Ar = bicyclic aryl, heteroaryl; Y, Z = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl.

(CH2)nCO2H, (CH2)nV, etc.; n = 0-2; V = Q2-Q5, tetrazolyl, PO3H2, cyano, etc.; W = OR10; R10 = H, protecting group, amino, alkylamino, hydroxyamino, α-amino acid residue, etc.; with a proviso, were prepared. Thus, 2-[[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methoxy-4-carboxylic acid (solution phase preparation given) at 1 μM gave 98.4% inhibition of 125I-endothelin-1 binding to cell membranes.

IT 168468-14-2P 168468-15-3P 168468-17-5P
168468-19-7P 168468-21-1P 168468-23-3P
168468-25-5P 168468-26-6P 168468-28-8P
168468-29-9P 168468-30-2P 168468-32-4P
168468-34-6P 168468-36-8P 168468-38-0P
168468-40-4P 168468-41-5P 168468-43-7P
168468-45-9P 168468-47-1P 168468-49-3P
168468-51-7P 168468-53-9P 168468-55-1P
168468-57-3P 168468-59-5P 168468-61-9P
168468-63-1P 168468-65-3P 168468-67-5P
168468-69-7P 168468-71-1P 168468-73-3P
168468-74-4P 168468-75-5P 168468-76-6P
168468-78-8P 168468-79-9P 168468-81-3P
168468-83-5P 168468-84-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates and related compds. as endothelin antagonists)

RN 168468-14-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-13-1
CMF C28 H38 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-15-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-17-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-phenyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-16-4
CMF C33 H40 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 168468-19-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-phenyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-18-6
CMF C34 H42 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 168468-21-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-ethyl-2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-20-0
CMF C29 H40 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-23-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-propyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-22-2
CMP C30 H42 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-25-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-(1-methylethyl)-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-24-4
CMP C30 H42 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 168468-26-6 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 5-cyclopropyl-2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-28-8 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-27-7
CMP C30 H42 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-29-9 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-30-2 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-1,5-dimethyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-32-4 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-1-(phenylmethyl)-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-31-3
CMP C35 H44 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-34-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[cyclohexylamino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-33-5
CMP C28 H38 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-36-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[2-[[4-(methoxymethoxy)-1-piperidinyl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-35-7
CMP C29 H40 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-38-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]sulfonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 168468-37-9
CMP C27 H38 N6 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-40-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[1,1-dimethylethoxy]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-39-1
CMP C26 H35 N5 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 168468-41-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[phenylmethyl]amino]carbonyl]amino]pentyl]amino]ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-43-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[phenylacetyl]amino]pentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-42-6
CMP C29 H33 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-45-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-44-8
CMP C29 H39 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-47-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cycloheptylcarbonyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-46-0
CMP C29 H39 N5 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 168468-49-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 168468-48-2
CMP C30 H39 N5 O4



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-51-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[2-[[4-methoxyphenyl]acetyl]amino]-4-methyl-1-oxopentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-50-6
CMP C30 H35 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-53-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(3,3-dimethyl-1-oxobutyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-52-8
CMP C27 H37 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-55-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[1-oxo-2-propylpentyl]amino]pentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-54-0
CMP C29 H41 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 168468-57-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[3-pyridinylcarbonyl]amino]pentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-56-2
CMF C27 H30 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 168468-59-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-58-4
CMF C29 H40 N6 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 168468-61-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 168468-60-8
CMF C30 H40 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 168468-63-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [1(1R)-[1 α[1R*(S*)],4β]]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 168468-62-0
CMF C29 H40 N6 O5

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 168468-65-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 168468-64-2
CMF C30 H42 N6 O4



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 168468-67-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-66-4
CMF C30 H42 N6 O4




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 168468-69-7 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(4-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 168468-68-6
CMP C30 H42 N6 O4




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 168468-71-1 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclopentylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 168468-70-0
CMP C28 H38 N6 O4

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 168468-73-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cycloheptylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 168468-72-2
CMP C30 H42 N6 O4

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 168468-74-4 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylmethylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-75-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-ethyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-76-6 CAPLUS
CN 1H-imidazole-4,5-dicarboxylic acid, 2-[1-[[2-[[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-78-8 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]methylamino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-79-9 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]methylamino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168468-81-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[cyclohexyloxy]carbonyl]amino]-4-methyl-1-oxopentyl]methylamino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1



RN 168468-84-6 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[cyclohexyloxy]carbonyl]amino]-4-methyl-1-oxopentyl]methylamino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 168468-27-7P 168470-54-0P 168470-55-1P
168470-58-4P 168470-59-5P 168470-60-8P
168470-61-9P 168470-62-0P 168470-63-1P
168470-65-3P 168470-66-4P 168470-67-5P
168470-70-0P 168470-71-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [(aminocarbonyl)leucylamino]indolylethylazocarboxylates and related comds. as endothelin antagonists)

RN 168468-27-7 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[hexahydro-1H-azepin-1-yl]carbonyl]amino]-4-methyl-1-oxopentyl]methylamino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-54-0 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[[phenylmethoxy]carbonyl]amino]ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


CRN 168468-80-2
CMF C29 H39 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 168468-83-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[phenylamino]carbonyl]amino]pentyl]amino]ethyl]-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-82-4
CMF C29 H34 N6 O4


Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

Absolute stereochemistry.




RN 168470-55-1 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-58-4 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[[[1,1-dimethylethoxy]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-59-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[phenylmethoxy]carbonyl]amino]pentyl]amino]ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-60-8 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, (R-(R*,S*))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-61-9 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-62-0 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-amino-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-63-1 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (S-(R*,S*))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-65-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-66-4 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-amino-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-67-5 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, (S-(R*,S*))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168470-70-0 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-(methylamino)-1-oxopentyl]amino]ethyl]-, phenylmethyl ester, (R-(R*,S*))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-71-1 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylamino)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (S-(R*,S*))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM
ACCESSION NUMBER: 1995:804314 CAPLUS
DOCUMENT NUMBER: 123:228900
TITLE: Preparation of azole-fused peptides as substance P antagonists and analgesics.
INVENTOR(S): Morgan, Barry A.; Gordon, Thomas D.; Hansen, Philip E.; Singh, Jasbir
PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
SOURCE: U.S., 34 pp. Cont. of U.S. Ser. No. 131,706, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5378803	A	19950103	US 1992-912949	19920710
PRIORITY APPLN. INFO.:			US 1992-912949	B1 19920710
			US 1987-131706	19871211

OTHER SOURCE(S): MARPAT 123:228900
OI



AB Title compde. [I; Q1 = Pro, bond; Q2 = Pro, D-Trp, bond; Q3 = Pro, D-Trp,

Phe, (R)-(2,3,4,9-tetrahydro)-1H-pyrido[3,4-b]indol-2-yl-3-carbonyl, bond; Q4 = Pro, D-Trp, Phe, bond; Q5 = D-Trp, Phe, bond; Q6 = Leu, Met, bond; Q7 = Phe, N-MePhe, Met, bond; R1 = H, Z, BOC; R2 = H; R3 = MeICH, Me2CHCH2, H2N(CH2)4, PhCH2, 4-HOC6H4CH2, pyridylmethyl, (1H-indol-3-yl)methyl; R2R3 = atoms to form 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2,3-diyl; R5 = H, OH or alkali metal salt thereof, MeO, EtO, amino, etc.; X = oxa this, imido; Y = oxo, H2; n = 0,1; starred center is L or D; with a proviso), were prepared. Thus, title compound (II; starred center has D-configuration), prepared via thionation of Z-D-Trp-NH2 with P2S5 and cyclocondensation of the product with Et 3-chloro-2-oxo-3-phenylpropionate, antagonized substance P in the guinea pig ileum test with pA2 = 7.3, and in the mouse acetylcholine-induced writhing test showed intrathecal ED50 = 0.78 µg/mouse.


IT 144310-80-5P 168110-20-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole-fused peptides as substance P antagonists and analgesics)

RN 144310-80-5 CAPLUS

CN L-Phenylalaninamide, N-[[2-[2-(1H-indol-3-yl)-1-[(2-pyrrolidinylcarbonyl)amino]ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168110-20-1 CAPLUS

CN L-Phenylalaninamide, N-[[2-[2-(1H-indol-3-yl)-1-[(2-pyrrolidinylcarbonyl)amino]ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, [R-(R*,S*)]-, phosphata (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 144310-80-5
CMP CS1 H56 N10 OS

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMP H3 O4 P




IT 132407-19-3P 150439-60-4P 167983-24-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azole-fused peptides as substance P antagonists and analgesics)

RN 132407-19-3 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[[(phenylmethoxy)carbonyl]amino]ethyl]-5-phenyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150439-60-4 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[[(phenylmethoxy)carbonyl]amino]ethyl]-5-phenyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167983-24-6 CAPLUS

CN L-Phenylalaninamide, N-[[2-[2-(1H-indol-3-yl)-1-[[[(phenylmethoxy)carbonyl]amino]ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167983-25-7 CAPLUS

CN L-Phenylalaninamide, N-[[2-[1-amino-2-(1H-indol-3-yl)ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 167983-26-8 CAPLUS

CN L-Phenylalaninamide, N-[[2-[1-[[[1-(1,1-dimethylethoxy)carbonyl]-2-pyrrolidinyl]carbonyl]amino]-2-(1H-indol-3-yl)ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 2-A



L11 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:640904 CAPLUS

DOCUMENT NUMBER: 119:240904

TITLE: Peptida azoles: a new class of biologically-active dipeptidic mimetics

AUTHOR(S): Gordon, Tom; Hansen, Philip; Morgan, Barry; Singh, Jasbir; Baizman, Eugene; Ward, Susan

CORPORATE SOURCE: Dep. Med. Chem., Starling Winthrop Pharm. Res. Div., Rensselaer, NY, 12144, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(5), 915-20

CODEN: BMCLEB; ISSN: 0960-894X

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Appropriately substituted thiazoles, imidazoles and oxazoles have been designed to be useful mimetics of dipeptide moieties, these "peptide azoles" have been shown to be potent antagonists of substance P as measured by isolated tissue assays such as the isolated guinea-pig ileum. A novel, chiral synthesis of these peptida azoles from amino acids has been developed.


IT 150439-60-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with peptide derivative)
RN 150439-60-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-
[(phenylmethoxy)carbonyl]amino]ethyl]-5-phenyl-, methyl ester, (R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 150439-62-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and substance P antagonist activity of)
RN 150439-62-6 CAPLUS
CN L-Phenylalaninamide, N-[[2-[2-(1H-indol-3-yl)-1-[(2-pyrrolidinylcarbonyl)amino]ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-L-phenylalanyl-D-tryptophyl-L-leucyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




L11 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:428591 CAPLUS
DOCUMENT NUMBER: 119:28591
TITLE: Synthetic approaches to the azole peptide mimetics
AUTHOR(S): Gordon, Thomas D.; Singh, Jasbir; Hansen, Philip E.; Morgan, Barry A.
CORPORATE SOURCE: Dep. Med. Chem., Sterling Winthrop Pharm. Res. Div., Kenilworth, NY, 12144, USA
SOURCE: Tetrahedron Letters (1993), 34(12), 1901-4
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 119:28591
GI



AB The synthesis of dipeptide mimetics I (X = S, O, NH, NMe; R = PhCH2O2C, Me3C; R1 = 3-indolyl, Ph; R2 = Ph, 2-naphthyl, 3-pyridyl, CHMe2, Me; cyclohexyl) from beta-keto dipeptides R-L-NHCH(CH2R1)CO-DL-NHCH(COR2)CO2Me have been developed. The thiazoles, imidazoles, and oxazoles I are obtained with a high degree of retention of configuration at Ha.


IT 148123-90-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, via cyclocondensation of keto dipeptide with ammonium acetate)
RN 148123-90-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-
[(phenylmethoxy)carbonyl]amino]ethyl]-5-phenyl-, methyl ester, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 148123-86-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, via cyclocondensation of keto dipeptide with methylamine)
RN 148123-86-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-
[(phenylmethoxy)carbonyl]amino]ethyl]-1-methyl-5-phenyl-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:18658 CAPLUS
DOCUMENT NUMBER: 118:18658
TITLE: Quantitative analysis of collagen and elastin cross-links using a single-column system
AUTHOR(S): Sims, Trevor J.; Bailey, Allen J.
CORPORATE SOURCE: Dep. Vet. Med., Univ. Bristol, Langford/Bristol, BS18 7DY, UK
SOURCE: Journal of Chromatography (1992), 582(1-2), 49-55
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The separation of both the immature and mature cross-links present in collagen together with the stable cross-links of elastin has been achieved on a single ion-exchange column. This technique avoids the current necessity for two different systems, ion-exchange and high-performance liquid chromatog.-fluorescence techniques. The value of the method is illustrated by the comparison of the cross-link contents of aging bovine skin, from fetal to old age.

IT 108212-74-4
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in collagens and elastins by cation-exchange liquid chromatog.)

RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, alpha-amino-4-(2-amino-2-carboxyethyl)-
N-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)



L11 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1992:604556 CAPLUS
DOCUMENT NUMBER: 117:204556
TITLE: Antagonists that demonstrate species differences in neurokinin-1 receptors
AUTHOR(S): Appell, Kenneth C.; Fragale, Barbara J.; Loscig, Jane; Singh, Saira; Tomczuk, Bruce E.
CORPORATE SOURCE: Dep. Enzymol. Biochem., Sterling Res. Group, Malvern, PA, 19355, USA
SOURCE: Molecular Pharmacology (1992), 41(4), 772-8
CODEN: MOPMA3; ISSN: 0026-895X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 125I-Bolton-Hunter-substance P (125I-BH-SP) binding properties of three novel classes of neurokinin-1 (NK-1) receptor antagonists were investigated in tissues derived from humans, guinea pigs, and rats. 125I-BH-SP was shown to bind to a single class of binding sites, with similar dissociation constants, Kd, in human astrocytoma cells (U-373 MG), human urinary bladder, guinea pig forebrain, guinea pig ileum longitudinal smooth muscle, rat forebrain, and rat duodenum. In each tissue preparation, known peptide agonists and peptide antagonists yielded potencies typical for a NK-1 receptor profile, with little difference in binding properties between the various tissues. However, when the three classes of compounds, heterosteroids, cyanines, and modified peptides, were tested for their ability to displace 125I-BH-SP binding from the NK-1 receptor, very different binding profiles were observed. The heterosteroids were shown to be as much as 3 orders of magnitude more potent in tissues derived from rats than from humans or guinea pigs. A distinct species-dependent structure-activity relationship (SAR) was also observed for this class of compounds. Like the heterosteroids, the cyanines displaced 125I-BH-SP with 10-30-fold higher affinity in rat tissues than in human and guinea pig tissues. However, the SAR generated by the cyanines was comparable in all tissues studied. The modified peptides, on the other hand, were up to 10-100-fold more potent in human and guinea pig than rat tissues, producing a SAR that differed between the various species. No differences in binding properties between central nervous system and peripheral tissues from the same species were seen with these compounds. These results provide evidence for species differences in NK-1 receptors in humans, guinea pigs, and rats. Because it is known that there exists great sequence identity between rat and human NK-1 receptors, it is hypothesized that key amino acid changes or different lipid environments within the transmembrane binding region of the receptor may account for the observed species difference. Furthermore, this study emphasizes that caution is necessary in the choice of species to be used in development programs targeted towards therapeutic entities in the NK-1 receptor antagonist area.

IT 144310-80-5
RL: BIOL (Biological study)
(neurokinin-1 receptor binding of, structure in relation to)

RN 144310-80-5 CAPLUS
CN L-Phenylalaninamide, N-[[2-[2-(1H-indol-3-yl)-1-[(2-pyrrolidinylcarbonyl)amino]ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, [R-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:674700 CAPLUS
DOCUMENT NUMBER: 115:274700
TITLE: Collagen cross-linking in sun-exposed and unexposed sites of aged human skin
AUTHOR(S): Yamauchi, Mitsuo; Prissayanh, Philip; Haque, Zia; Woodley, David T.
CORPORATE SOURCE: Dent. Res. Cent., Univ. North Carolina, Chapel Hill, NC, 27599-7455, USA
SOURCE: Journal of Investigative Dermatology (1991), 97(5), 936-41
CODEN: JIDSAE; ISSN: 0022-202X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A recently described nonreducible, acid-heat stable compound, histidinohydroxylysine (HHL), is a collagen crosslink isolated from mature skin tissue. Its abundance is related to chronol. aging of skin. The present communication describes the quantity of HHL from aged human skin of the same individuals in sun-exposed (wrist) and unexposed (buttock) sites. Punch biopsies were obtained from these sites from 9 people of age 60 or older. HHL contents (moles/mol of collagen) at these sites were for wrist 0.13 and for buttock 0.69 (mean). Acute irradiation of the crosslinked peptides with UVA (up to 250 J/cm²) and UVB (up to 1 J/cm²) had no effect on HHL structure. The same treatment degraded another nonreducible, stable collagen crosslink, pyridinoline. Chronic sunlight exposure may be associated with an impediment to normal maturation of human dermal collagen resulting in tenuous amount of HHL. Thus, the process of photoaging in dermal collagen is different from that of chronol. aging in human skin.

IT 108212-74-4
RL: BIOL (Biological study)
(of collagen of sun-exposed and unexposed sites in aged human skin)
RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, α-amino-4-(2-amino-2-carboxyethyl)-c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]-(9CI) (CA INDEX NAME)




L11 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:226346 CAPLUS
DOCUMENT NUMBER: 114:226346
TITLE: Collagen cross-linking in bovine gingiva
AUTHOR(S): Tanner, J. H.; Yamauchi, M.; Simpson, D. M.
CORPORATE SOURCE: Dent. Res. Cent., Univ. North Carolina, Chapel Hill, NC, 27599-7455, USA
SOURCE: Archives of Oral Biology (1991), 36(2), 111-15
CODEN: AOBIAE; ISSN: 0003-9969
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tissue samples from 5 different sites of 6 bovine mandibles were used to quantify collagen crosslinks as moles crosslink per mol of collagen. Gingiva contained primarily 3 reducible crosslinks dehydro-dihydroxylysine, dehydro-histidinohydroxymerodesmosine and dehydro-histidinohydroxylysine (I) and relatively small amounts of nonreducible crosslinks. The crosslink d. varied from site to site within the same mandible. I showed the most significant increase from anterior to posterior; the content in the retromolar region was 3-fold greater than in the anterior lingual site. Histol., the posterior samples, especially the retromolar gingiva, contained less mature (thinner) collagen bundles. These findings suggest that the maturity of bovine mandibular gingival collagen varies at different sites.

IT 108212-74-4
RL: BIOL (Biological study)
(of crosslinked collagen in gingiva)


RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, α-amino-4-(2-amino-2-carboxyethyl)-c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]-(9CI) (CA INDEX NAME)



L11 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:102788 CAPLUS
DOCUMENT NUMBER: 114:102788
TITLE: Synthetic approaches to the azole peptide mimetics
AUTHOR(S): Gordon, Thomas D.; Hansen, Philip E.; Morgan, Barry A.; Singh, Jasbir
CORPORATE SOURCE: Dep. Med. Chem., Sterling Res. Group, Rensselaer, NY, 12144, USA
SOURCE: Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 11th (1990), Meeting Date 1989, 680-1. Editor(s): Rivier, Jean E.; Marshall, Garland R. ESCOM Sci. Pub.: Leiden, Neth.


DOCUMENT TYPE: Conference
LANGUAGE: English
GI

CODEN: 56KTA7



AB A symposium report on the synthesis of title peptides I (X = S, NH, O).
IT 132407-19-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 132407-19-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[(phenylmethoxy)carbonyl]amino]ethyl]-5-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:219445 CAPLUS
DOCUMENT NUMBER: 108:219445
TITLE: Aging and cross-linking of skin collagen
AUTHOR(S): Yamauchi, Mitsuo; Woodley, David T.; Mechanic, Gerald L.
CORPORATE SOURCE: Dent. Res. Cent., Univ. North Carolina, Chapel Hill, NC, 27514-7455, USA
SOURCE: Biochemical and Biophysical Research Communications (1988), 152(2), 898-903
CODEN: BBRCAG; ISSN: 0006-291X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The abundance of histidinohydroxylysine, a crosslink in collagen, was clearly demonstrated to be related to the chronol. aging of

an organism. Quantification of the crosslink in bovine and human skin of various ages indicated that it rapidly increases from birth through maturation. Subsequently, a steady increase occurs with aging, approaching 1 mol/mol collagen. This compound seemed to be related to the relative proportions of soluble to insol. collagen from skin in neutral salt, dilute acid, and denaturing aqueous solvents (higher concentration in the insol.

portion). It was absent from other major collagenous tissues such as dentin, bone, and tendon.

IT 108212-74-4
RL: BIOL (Biological study)
(as collagen crosslink, of skin of human and laboratory animal in ontogeny)
RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, α-amino-4-(2-amino-2-carboxyethyl)-c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]-(9CI) (CA INDEX NAME)




L11 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:613733 CAPLUS
DOCUMENT NUMBER: 107:213733
TITLE: Structure and formation of a stable histidine-based trifunctional cross-link in skin collagen
AUTHOR(S): Yamauchi, Mitsuo; London, Robert E.; Guenat, Christian; Hashimoto, Fusazo; Mechanic, Gerald L.
CORPORATE SOURCE: Dent. Res. Cent., Univ. North Carolina, Chapel Hill, NC, 27514, USA
SOURCE: Journal of Biological Chemistry (1987), 262(24), 11428-34
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English


AB A stable nonreducible trifunctional crosslinking amino acid was isolated from mature bovine skin collagen fibrils. Previous crosslink peptide isolations and amino acid analyses indicate the compound has properties identical with those of hydroxyaldohistidine. Its newly proposed structure was verified by using fast atom bombardment mass spectrometry, and 1H and 13C NMR. The data indicated that the crosslink consists of the prosthetic groups from one residue each of histidine, hydroxylysine, and lysine. The 1H and 13C NMR data indicated that imidazole C-2 of histidine is linked to C-6 of norleucine (ε-deaminated lysine residue) which in turn is linked to the C-6 amino group of hydroxylysine. Based on the trivial names for other crosslinking residues found in collagen and elastin it was given the name histidinohydroxylysine. In vitro incubation studies for 524 wk, in aqueous solution at physiol. pH and ionic strength, with 6-mo-old bovine embryo skin demonstrated a 1:1 stoichiometric relationship between the disappearance of the labile reducible bifunctional crosslink dehydrohydroxylysine and the appearance of histidinohydroxylysine. These results can partially explain the previously observed disappearance of dehydrohydroxylysine with chronol. age.

IT 108212-74-4P
RL: PREP (Preparation)
(structure and formation of, as trifunctional crosslink in skin collagen)

RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, α -amino-4-(2-amino-2-carboxyethyl)-
c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX
NAME)



L11 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:419681 CAPLUS
DOCUMENT NUMBER: 107:19681
TITLE: Locus of a histidine-based, stable trifunctional,
helix to helix collagen cross-link: stereospecific
collagen structure of type I skin fibrils
AUTHOR(S): Mechanic, Gerald L.; Katz, Elton P.; Henmi, Masayuki;
Noyes, Claudia; Yamauchi, Mitsuo
CORPORATE SOURCE: Dent. Res. Cent., Univ. North Carolina, Chapel Hill,
NC, 27514, USA
SOURCE: Biochemistry (1987), 26(12), 3500-9
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The loci of the 3 amino acid residues that contribute their prosthetic
groups to form the stable, nonreducible, trifunctional intermol. crosslink
histidino(hydroxylysino)norleucine in skin collagen fibrils were
identified. Two apparently homogeneous 3-chained
histidino(hydroxylysino)norleucine crosslinked peptides were chromatog.
isolated. They were obtained from a tryptic digest of denatured unreduced
6M guanidine hydrochloride-insol. bovine skin collagen. Amino acid and
sequence analyses demonstrated that the prosthetic groups of
 $\alpha 1(I)$ -chain hydroxylysine-87, $\alpha 1(I)$ -chain lysine-16c, and
 $\alpha 2(I)$ -chain histidine-92 formed the crosslink. The latter results
served to define the locus of the stable, nonreducible trifunctional
moiety. Identical types of analyses were performed on the 3-chained
peptides isolated after bacterial collagenase digestion of the crosslinked
tryptic peptides. This confirmed the initial identification and location
of the 3 peptides linked by the crosslink. In addition, the data provide for
a correction of the micromol. structure for the $\alpha 2(I)$ chain.
Stereochem. considerations concerning the trifunctional crosslink's
specific locus indicate that the steric relationships between the α
chains of skin and skeletal tissue collagens are fundamentally different
and the intermol. relationships in skin fibrils are specific for skin.
The same mol. relationships also indicate that
histidino(hydroxylysino)norleucine links 3 mole. of collagen. The
stereochem. of crosslinking for skin collagen is in accordance with and
explains the previous x-ray findings of a 65-nm periodicity found for this
tissue.
IT 108212-74-4
RL: BIOL (Biological study)
(as crosslink between chains of type I collagen of skin fibrils)
RN 108212-74-4 CAPLUS
CN 1H-Imidazole-2-hexanoic acid, α -amino-4-(2-amino-2-carboxyethyl)-
c-[(5-amino-5-carboxy-2-hydroxypentyl)amino]- (9CI) (CA INDEX
NAME)



=>